BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256-265. [PMID: 23291374 DOI: 10.1093/jnci/djs629] [Cited by in Crossref: 660] [Cited by in F6Publishing: 716] [Article Influence: 66.0] [Reference Citation Analysis]
Number Citing Articles
1 Liljedahl E, Konradsson E, Gustafsson E, Jonsson KF, Olofsson JK, Osther K, Ceberg C, Redebrandt HN. Combined anti-C1-INH and radiotherapy against glioblastoma. BMC Cancer 2023;23:106. [PMID: 36717781 DOI: 10.1186/s12885-023-10583-1] [Reference Citation Analysis]
2 Ji X, Jiang W, Wang J, Zhou B, Ding W, Liu S, Huang H, Chen G, Sun X. Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. Front Immunol 2022;13:1106644. [PMID: 36713375 DOI: 10.3389/fimmu.2022.1106644] [Reference Citation Analysis]
3 Holtkamp LHJ, Lo S, Drummond M, Thompson JF, Nieweg OE, Hong AM. Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma. Clin Oncol (R Coll Radiol) 2023;35:e85-93. [PMID: 35851490 DOI: 10.1016/j.clon.2022.06.012] [Reference Citation Analysis]
4 Ghafelehbashi R, Farshbafnadi M, Aghdam NS, Amiri S, Salehi M, Razi S. Nanoimmunoengineering strategies in cancer diagnosis and therapy. Clin Transl Oncol 2023;25:78-90. [PMID: 36076122 DOI: 10.1007/s12094-022-02935-3] [Reference Citation Analysis]
5 Hu X, Yu L, Bian Y, Zeng X, Luo S, Wen Q, Chen P. Paclitaxel-loaded tumor cell-derived microparticles improve radiotherapy efficacy in triple-negative breast cancer by enhancing cell killing and stimulating immunity. Int J Pharm 2022;632:122560. [PMID: 36586632 DOI: 10.1016/j.ijpharm.2022.122560] [Reference Citation Analysis]
6 Saidian A, Dolendo I, Sharabi A, Stewart TF, Rose B, McKay RR, Bagrodia A, Salmasi A. The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers. Cancers (Basel) 2022;15. [PMID: 36612124 DOI: 10.3390/cancers15010127] [Reference Citation Analysis]
7 Li Z, Ke X, Zuo D, Wang Z, Fang F, Li B. New Insights into the Relationship between Gut Microbiota and Radiotherapy for Cancer. Nutrients 2022;15. [PMID: 36615706 DOI: 10.3390/nu15010048] [Reference Citation Analysis]
8 Rodríguez Pérez A, Felip Font E, Chicas-sett R, Montero-luis Á, de Paz Arias L, González-del-alba A, López-campos F, López López C, Hernando Requejo O, Conde-moreno AJ, Arranz Arija JÁ, de Castro Carpeño J. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer. Clin Transl Oncol 2022. [DOI: 10.1007/s12094-022-03011-6] [Reference Citation Analysis]
9 Zhang D, He J, Zhou M. Radiation-assisted strategies provide new perspectives to improve the nanoparticle delivery to tumor. Adv Drug Deliv Rev 2022;193:114642. [PMID: 36529190 DOI: 10.1016/j.addr.2022.114642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ng SSW, Dawson LA. Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma. Biomedicines 2022;10. [PMID: 36551971 DOI: 10.3390/biomedicines10123215] [Reference Citation Analysis]
11 Vilas-Boas I, Moreira I, Rodrigues A. A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy. Cureus 2022;14:e32585. [PMID: 36654654 DOI: 10.7759/cureus.32585] [Reference Citation Analysis]
12 Zheng D, Li Y, Song L, Xu T, Jiang X, Yin X, He Y, Xu J, Ma X, Chai L, Xu J, Hu J, Mi P, Jing J, Shi H. Improvement of radiotherapy with an ozone-carried liposome nano-system for synergizing cancer immune checkpoint blockade. Nano Today 2022;47:101675. [DOI: 10.1016/j.nantod.2022.101675] [Reference Citation Analysis]
13 Alden RS, Kamran MZ, Bashjawish BA, Simone BA. Glutamine metabolism and radiosensitivity: Beyond the Warburg effect. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1070514] [Reference Citation Analysis]
14 Berg-larsen A, Mobergslien A, Moen I, Petros G, Kristian A, Gunvaldsen KS, Cruciani V, Wickstroem K, Bjerke RM, Karlsson J, Cuthbertson A. Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1033303] [Reference Citation Analysis]
15 Jungles KM, Holcomb EA, Pearson AN, Jungles KR, Bishop CR, Pierce LJ, Green MD, Speers CW. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1022542] [Reference Citation Analysis]
16 Craig DJ, Ambrose S, Stanbery L, Walter A, Nemunaitis J. Systemic benefit of radiation therapy via abscopal effect. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.987142] [Reference Citation Analysis]
17 Baiocco G, Bartzsch S, Conte V, Friedrich T, Jakob B, Tartas A, Villagrasa C, Prise KM. A matter of space: how the spatial heterogeneity in energy deposition determines the biological outcome of radiation exposure. Radiat Environ Biophys 2022. [PMID: 36220965 DOI: 10.1007/s00411-022-00989-z] [Reference Citation Analysis]
18 Song Z, Lu L, Gao Z, Zhou Q, Wang Z, Sun L, Zhou Y. Immunotherapy for liposarcoma: emerging opportunities and challenges. Future Oncol 2022. [PMID: 36214331 DOI: 10.2217/fon-2021-1549] [Reference Citation Analysis]
19 Jiang L, Lyu Q, Abdelhamid AMH, Hui S, Sheng K. An efficient rectangular optimization method for sparse orthogonal collimator based small animal irradiation. Phys Med Biol 2022;67:195010. [DOI: 10.1088/1361-6560/ac910b] [Reference Citation Analysis]
20 Wang N, Zhang X, Sui J, Wang Y, Wu Y, Lei Q, Tu H, Yang L, Liu Y, Yang M, Yang H, Li D, Lei Z. Radiation-induced eosinophil increase ratio predicts patient outcomes in non-small celllung cancer. Front Oncol 2022;12:999555. [DOI: 10.3389/fonc.2022.999555] [Reference Citation Analysis]
21 Yomo S, Oda K, Oguchi K. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores. Journal of Neurosurgery 2022. [DOI: 10.3171/2022.9.jns221215] [Reference Citation Analysis]
22 Sultanpuram NR, Ahmed U, Peters JT, Zhang T, Wang AZ. TISSUE ENGINEERED CANCER METASTASES AS CANCER VACCINE TO IMPROVE CANCER IMMUNOTHERAPY. Acta Biomater 2022:S1742-7061(22)00633-X. [PMID: 36174938 DOI: 10.1016/j.actbio.2022.09.059] [Reference Citation Analysis]
23 Matsui JK, Perlow HK, Raj RK, Nalin AP, Lehrer EJ, Kotecha R, Trifiletti DM, Mcclelland S, Kendra K, Williams N, Owen DH, Presley CJ, Thomas EM, Beyer SJ, Blakaj DM, Ahluwalia MS, Raval RR, Palmer JD. Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. Biomedicines 2022;10:2211. [DOI: 10.3390/biomedicines10092211] [Reference Citation Analysis]
24 Bote H, Mesas A, Baena J, Herrera M, Paz-Ares L. Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs 2022;27:289-300. [PMID: 36203360 DOI: 10.1080/14728214.2022.2113377] [Reference Citation Analysis]
25 Lee SF, Yip PL, Wong A, Ng F, Koh V, Wong LC, Luk H, Ng CK, Lee FAS, Mamon HJ. Splenic irradiation contributes to grade ≥ 3 lymphopenia after adjuvant chemoradiation for stomach cancer. Clin Transl Radiat Oncol 2022;36:83-90. [PMID: 35909437 DOI: 10.1016/j.ctro.2022.07.007] [Reference Citation Analysis]
26 Guduru ATKVVNSK, Manav N, Mansuri A, Gupta I, Bhatia D, Kumar A, Dalvi SV. NIR-Active Porphyrin-Decorated Lipid Microbubbles for Enhanced Therapeutic Activity Enabled by Photodynamic Effect and Ultrasound in 3D Tumor Models of Breast Cancer Cell Line and Zebrafish Larvae. ACS Appl Bio Mater 2022. [PMID: 35960932 DOI: 10.1021/acsabm.2c00483] [Reference Citation Analysis]
27 Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258. [PMID: 35906199 DOI: 10.1038/s41392-022-01102-y] [Reference Citation Analysis]
28 Sengedorj A, Hader M, Frey B, Fietkau R, Ott OJ, Gaipl US, Rückert M. Interaction of Radiotherapy and Hyperthermia with the Immune System: a Brief Current Overview. Curr Stem Cell Rep. [DOI: 10.1007/s40778-022-00215-y] [Reference Citation Analysis]
29 Liljedahl E, Konradsson E, Gustafsson E, Jonsson KF, Olofsson JK, Ceberg C, Redebrandt HN. Long-term anti-tumor effects following both conventional radiotherapy and FLASH in fully immunocompetent animals with glioblastoma. Sci Rep 2022;12:12285. [PMID: 35853933 DOI: 10.1038/s41598-022-16612-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ji H, Zhou Z. A ‘Hybrid’ Radiotherapy Regimen Designed for Immunomodulation: Combining High-Dose Radiotherapy with Low-Dose Radiotherapy. Cancers 2022;14:3505. [DOI: 10.3390/cancers14143505] [Reference Citation Analysis]
31 Sun R, Henry T, Laville A, Carré A, Hamaoui A, Bockel S, Chaffai I, Levy A, Chargari C, Robert C, Deutsch E. Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy? J Immunother Cancer 2022;10:e004848. [PMID: 35793875 DOI: 10.1136/jitc-2022-004848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Baré M, Poeta S, Fernandes P, Jourani Y, Otte F, Van Brussel S, Van Gestel D, Van den Begin R. Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study. Physics and Imaging in Radiation Oncology 2022;23:127-133. [DOI: 10.1016/j.phro.2022.07.006] [Reference Citation Analysis]
33 Han Y, Sun J, Wei H, Hao J, Liu W, Wang X. Ultrasound-Targeted Microbubble Destruction: Modulation in the Tumor Microenvironment and Application in Tumor Immunotherapy. Front Immunol 2022;13:937344. [DOI: 10.3389/fimmu.2022.937344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Vladimirova LY, Popova IL, Abramova NA, Teplyakova MA, Tikhanovskaya NM, Lianova AA, Storozhakova AE, Ryadinskaya LA, Kabanov SN, Kalabanova EA. Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation). Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-9-186-192] [Reference Citation Analysis]
35 Skwierawska D, López-Valverde JA, Balcerzyk M, Leal A. Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment. Cancers (Basel) 2022;14:2865. [PMID: 35740531 DOI: 10.3390/cancers14122865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Sanmamed MF, Berraondo P, Rodriguez-ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer 2022;3:665-680. [DOI: 10.1038/s43018-022-00401-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Bootsma M, McKay RR, Emamekhoo H, Bade RM, Schehr JL, Mannino MC, Singh A, Wolfe SK, Schultz ZD, Sperger J, Xie W, Signoretti S, Kyriakopoulos CE, Kosoff D, Abel EJ, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Bassetti M, Floberg J, Yu M, Sethakorn N, Sharifi M, Harari PM, Choueiri TK, Lang JM, Zhao SG. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. J Clin Oncol 2022;:JCO2200219. [PMID: 35617646 DOI: 10.1200/JCO.22.00219] [Reference Citation Analysis]
38 Shim MK, Song SK, Jeon SI, Hwang KY, Kim K. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2081683] [Reference Citation Analysis]
39 Spieler B, Giret TM, Welford S, Totiger TM, Mihaylov IB. Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study. Biomedicines 2022;10:1173. [DOI: 10.3390/biomedicines10051173] [Reference Citation Analysis]
40 Sharma NK, Kappadath SC, Chuong M, Folkert M, Gibbs P, Jabbour SK, Jeyarajah DR, Kennedy A, Liu D, Meyer JE, Mikell J, Patel RS, Yang G, Mourtada F. The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors. Brachytherapy 2022. [DOI: 10.1016/j.brachy.2022.04.004] [Reference Citation Analysis]
41 Wang Y, Li Y, Sheng Z, Deng W, Yuan H, Wang S, Liu Y. Advances of Patient-Derived Organoids in Personalized Radiotherapy. Front Oncol 2022;12:888416. [DOI: 10.3389/fonc.2022.888416] [Reference Citation Analysis]
42 Hassel JC, Schank TE, Smetak H, Mühlbauer J, Salzmann M, Machiraju D, Menzer C, Lang K, König L, Haefner MF, Hülsmeyer I, Kohler C, Spang R, Enk A, Debus J, Beckhove P. Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). OncoImmunology 2022;11:2066609. [DOI: 10.1080/2162402x.2022.2066609] [Reference Citation Analysis]
43 Wu L, Wang Y, Li B, Wan G, Liang L, Li T, Lang J, Wang Q. Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT). Front Oncol 2022;12:878851. [DOI: 10.3389/fonc.2022.878851] [Reference Citation Analysis]
44 Germino EA, Govindarajan A, Sedrak MS, Li D, Amini A. Multimodality Treatment with Radiotherapy and Immunotherapy in Older Adults: Rationale, Evolving Data, and Current Recommendations. Seminars in Radiation Oncology 2022;32:142-54. [DOI: 10.1016/j.semradonc.2021.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hamon P, Gerbé De Thoré M, Classe M, Signolle N, Liu W, Bawa O, Meziani L, Clémenson C, Milliat F, Deutsch E, Mondini M. TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy. J Immunother Cancer 2022;10:e003519. [PMID: 35301235 DOI: 10.1136/jitc-2021-003519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Francisco Casesnoves. Radiotherapy Wedge Filter AAA Model 3d Simulations For 18 MEV 5cm-Depth Dose with Medical Physics Applications. IJSRCSEIT 2022. [DOI: 10.32628/cseit228141] [Reference Citation Analysis]
47 Zhai D, An D, Wan C, Yang K. Radiotherapy: Brightness and darkness in the era of immunotherapy. Transl Oncol 2022;19:101366. [PMID: 35219093 DOI: 10.1016/j.tranon.2022.101366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
48 Higgins KA, Puri S, Gray JE. Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2022;40:576-85. [PMID: 34985931 DOI: 10.1200/JCO.21.01707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
49 Di Molfetta S, Feola T, Fanciulli G, Florio T, Colao A, Faggiano A, Nike Group. Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver? J Clin Med 2022;11:1019. [PMID: 35207291 DOI: 10.3390/jcm11041019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
50 Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor MH, Bennouna J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL. Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor. Future Oncol 2022. [PMID: 35144482 DOI: 10.2217/fon-2021-0930] [Reference Citation Analysis]
51 Volovat S, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics 2022;14:397. [DOI: 10.3390/pharmaceutics14020397] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
52 Zhao X, Li J, Zheng L, Yang Q, Chen X, Chen X, Yu Y, Li F, Cui J, Sun J. Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non–Small-Cell Lung Cancer. Front Mol Biosci 2022;9:786864. [DOI: 10.3389/fmolb.2022.786864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Hamon P, de Thoré MG, Classe M, Signolle N, Liu W, Bawa O, Meziani L, Clémenson C, Milliat F, Deutsch E, Mondini M. TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy.. [DOI: 10.1101/2022.01.17.476557] [Reference Citation Analysis]
54 Cho Y, Kim Y, Chamseddine I, Lee WH, Kim HR, Lee IJ, Hong MH, Cho BC, Lee CG, Cho S, Kim JS, Yoon HI, Grassberger C. Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. Radiother Oncol 2022:S0167-8140(22)00011-1. [PMID: 35033601 DOI: 10.1016/j.radonc.2022.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
55 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
56 Kim S, Yeo MK, Kim JS, Kim JY, Kim KH. Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker. J Cancer 2022;13:162-73. [PMID: 34976180 DOI: 10.7150/jca.64082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Stephen B, Hajjar J. Immune System in Action. Adv Exp Med Biol 2021;1342:1-43. [PMID: 34972961 DOI: 10.1007/978-3-030-79308-1_1] [Reference Citation Analysis]
58 Spraker MB, Haarberg S, Ellis H, Van Tine BA. Concurrent Chemoradiation Therapy for Soft Tissue Sarcoma. Practical Guides in Radiation Oncology 2022. [DOI: 10.1007/978-3-031-06706-8_6] [Reference Citation Analysis]
59 Yavas G, Yavas C, Onal HC. Gynecological tumors. Advances in Magnetic Resonance Technology and Applications 2022. [DOI: 10.1016/b978-0-323-91689-9.00020-0] [Reference Citation Analysis]
60 Shaikh S. Molecular Imaging and Radiobiology. Advances in Imaging 2022. [DOI: 10.1007/978-981-16-9535-3_22] [Reference Citation Analysis]
61 Seniwal B, Thipe VC, Singh S, Fonseca TCF, Freitas de Freitas L. Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy. Front Oncol 2021;11:766407. [PMID: 34900715 DOI: 10.3389/fonc.2021.766407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
62 Mei E, Chen C, Li C, Ding X, Chen J, Xi Q, Zhou S, Liu J, Li Z. Injectable and Biodegradable Chitosan Hydrogel-Based Drug Depot Contributes to Synergistic Treatment of Tumors. Biomacromolecules 2021;22:5339-48. [PMID: 34813280 DOI: 10.1021/acs.biomac.1c01279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
63 Chin RI, Schiff JP, Brenneman RJ, Gay HA, Thorstad WL, Lin AJ. A Rational Approach to Unilateral Neck RT for Head and Neck Cancers in the Era of Immunotherapy. Cancers (Basel) 2021;13:5269. [PMID: 34771432 DOI: 10.3390/cancers13215269] [Reference Citation Analysis]
64 Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia 2021;23:1110-22. [PMID: 34619428 DOI: 10.1016/j.neo.2021.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
65 Luo M, Xia Y, Wang F, Zhang H, Su D, Su C, Yang C, Wu S, An S, Lin S, Fu L. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta Pharm Sin B 2021;11:3120-33. [PMID: 34729305 DOI: 10.1016/j.apsb.2021.03.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
66 Vaflard P, Paoletti X, Servois V, Tresca P, Pons-Tostivint E, Sablin MP, Ricci F, Loirat D, Hescot S, Torossian N, Bello Roufai D, Kamal M, Borcoman E, Le Tourneau C. Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy. Drugs R D 2021;21:399-406. [PMID: 34562258 DOI: 10.1007/s40268-021-00362-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Giuliani J, Fiorica F. Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer. J Oncol Pharm Pract 2021;:10781552211038925. [PMID: 34558362 DOI: 10.1177/10781552211038925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Zhang F, Manna S, Pop LM, Chen ZJ, Fu YX, Hannan R. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Semin Radiat Oncol 2020;30:129-38. [PMID: 32381292 DOI: 10.1016/j.semradonc.2019.12.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
69 Qing D, Peng L, Cen F, Huang X, Wei Q, Lu H. Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report. Front Oncol 2021;11:696422. [PMID: 34485132 DOI: 10.3389/fonc.2021.696422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Zhou B, Liu J, Lin M, Zhu J, Chen WR. Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. Coordination Chemistry Reviews 2021;442:214009. [DOI: 10.1016/j.ccr.2021.214009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
71 Henke LE, Stanley JA, Robinson C, Srivastava A, Contreras JA, Curcuru A, Green OL, Massad LS, Kuroki L, Fuh K, Hagemann A, Mutch D, McCourt C, Thaker P, Powell M, Markovina S, Grigsby PW, Schwarz JK, Chundury A. Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02726-7. [PMID: 34474109 DOI: 10.1016/j.ijrobp.2021.08.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
72 Kroese TE, Jairam J, Ruurda JP, Lin SH, Mohan R, Mook S, Haitjema S, Hoefer I, Haj Mohammad N, Peters M, van Hillegersberg R, van Rossum PSN. Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model. Radiother Oncol 2021;163:192-8. [PMID: 34453954 DOI: 10.1016/j.radonc.2021.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Feller G, Khammissa RAG, Nemutandani MS, Feller L. Biological consequences of cancer radiotherapy in the context of oral squamous cell carcinoma. Head Face Med 2021;17:35. [PMID: 34446029 DOI: 10.1186/s13005-021-00286-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Romiani A, Spetz J, Shubbar E, Lind DE, Hallberg B, Palmer RH, Forssell-Aronsson E. Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate. BMC Cancer 2021;21:950. [PMID: 34433438 DOI: 10.1186/s12885-021-08551-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Karachi A, Dastmalchi F, Nazarian S, Huang J, Sayour EJ, Jin L, Yang C, Mitchell DA, Rahman M. Optimizing T Cell-Based Therapy for Glioblastoma. Front Immunol 2021;12:705580. [PMID: 34421912 DOI: 10.3389/fimmu.2021.705580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
76 Asperud J, Arous D, Edin NFJ, Malinen E. Spatially fractionated radiotherapy: tumor response modelling including immunomodulation. Phys Med Biol 2021;66:175012. [DOI: 10.1088/1361-6560/ac176b] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Li JJ, Tsang JY, Tse GM. Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel) 2021;13:4233. [PMID: 34439387 DOI: 10.3390/cancers13164233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
78 Ellis R, Cole AJ, O'Hare J, Whitten G, Crowther K, Harrison C. Coincidental splenic irradiation and risk of functional hyposplenism in oesophageal cancer treatment. J Med Imaging Radiat Oncol 2021. [PMID: 34405578 DOI: 10.1111/1754-9485.13310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Leung CN, Howell DM, Howell RW. Radium-223 dichloride causes transient changes in natural killer cell population and cytotoxic function. Int J Radiat Biol 2021;:1-8. [PMID: 34264175 DOI: 10.1080/09553002.2021.1956002] [Reference Citation Analysis]
80 Du W, Frankel TL, Green M, Zou W. IFNγ signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol 2021. [PMID: 34385592 DOI: 10.1038/s41423-021-00735-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
81 Oweida A, Paquette B. Reconciling two opposing effects of radiation therapy: stimulation of cancer cell invasion and activation of anti-cancer immunity. Int J Radiat Biol 2021;:1-13. [PMID: 34264178 DOI: 10.1080/09553002.2021.1956005] [Reference Citation Analysis]
82 Goedegebuure RSA, Harrasser M, de Klerk LK, van Schooten TS, van Grieken NCT, Eken M, Grifhorst MS, Pocorni N, Jordanova ES, van Berge Henegouwen MI, Pouw RE, Verheul HMW, van der Vliet JJ, van Laarhoven HWM, Thijssen VLJL, Bass AJ, De Gruijl TD, Derks S. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. Oncoimmunology 2021;10:1954807. [PMID: 34377591 DOI: 10.1080/2162402X.2021.1954807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Liu N, Shan F, Ma M. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. Int Immunopharmacol 2021;99:108017. [PMID: 34352568 DOI: 10.1016/j.intimp.2021.108017] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Tarekegn K, Colon Ramos A, Singh B, Sequeira Gross HG, Gupta S. Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma. World J Oncol 2021;12:81-4. [PMID: 34349851 DOI: 10.14740/wjon1388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Parisi S, Napoli I, Lillo S, Cacciola A, Ferini G, Iatì G, Pontoriero A, Tamburella C, Davì V, Pergolizzi S. Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone. J Oncol Pharm Pract 2021;:10781552211027348. [PMID: 34233544 DOI: 10.1177/10781552211027348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
86 Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, Marguier A, Tochet F, Dosset M, Boustani J, Ravel P, Boidot R, Spehner L, Haicheur-Adjouri N, Marliot F, Pallandre JR, Bonnefoy F, Scripcariu V, Van den Eynde M, Cornillot E, Mirjolet C, Pages F, Adotevi O. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer 2021;9:e002256. [PMID: 34230108 DOI: 10.1136/jitc-2020-002256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
87 Cytlak UM, Dyer DP, Honeychurch J, Williams KJ, Travis MA, Illidge TM. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol 2021. [PMID: 34211187 DOI: 10.1038/s41577-021-00568-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
88 Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O. Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. BMC Immunol 2021;22:38. [PMID: 34144673 DOI: 10.1186/s12865-021-00429-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Wang Q, Li S, Qiao S, Zheng Z, Duan X, Zhu X. Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta-analysis. Front Immunol 2021;12:648652. [PMID: 34220806 DOI: 10.3389/fimmu.2021.648652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
90 Cavinato S, Felser T, Fusella M, Paiusco M, Montangero S. Optimizing radiotherapy plans for cancer treatment with Tensor Networks. Phys Med Biol 2021;66. [PMID: 34140431 DOI: 10.1088/1361-6560/ac01f2] [Reference Citation Analysis]
91 Lee HW. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. Int J Mol Sci 2021;22:6290. [PMID: 34208157 DOI: 10.3390/ijms22126290] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Fang T, Xiao J, Zhang Y, Hu H, Zhu Y, Cheng Y. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quant Imaging Med Surg 2021;11:2837-60. [PMID: 34079746 DOI: 10.21037/qims-20-173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Melillo G, Chand V, Yovine A, Gupta A, Massacesi C. Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Adv Ther 2021;38:2759-78. [PMID: 33881745 DOI: 10.1007/s12325-021-01675-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
94 Constanzo J, Faget J, Ursino C, Badie C, Pouget JP. Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway. Front Immunol 2021;12:680503. [PMID: 34079557 DOI: 10.3389/fimmu.2021.680503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
95 van Gisbergen MW, Zwilling E, Dubois LJ. Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio. Front Oncol 2021;11:653621. [PMID: 34041023 DOI: 10.3389/fonc.2021.653621] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Lippert TP, Greenberg RA. The abscopal effect: a sense of DNA damage is in the air. J Clin Invest 2021;131:148274. [PMID: 33938453 DOI: 10.1172/JCI148274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
97 He M, Yang T, Wang Y, Wang M, Chen X, Ding D, Zheng Y, Chen H. Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy. Adv Healthc Mater 2021;10:e2002104. [PMID: 33709564 DOI: 10.1002/adhm.202002104] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
98 Hanna CR, O'cathail SM, Graham J, Adams R, Roxburgh CS. Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. Journal of Immunotherapy and Precision Oncology 2021;4:86-104. [DOI: 10.36401/jipo-20-31] [Reference Citation Analysis]
99 Yoon K, Chen YJ, Chao J. A narrative review of combining radiation and immunotherapy in gastroesophageal cancers. Transl Cancer Res 2021;10:2586-95. [PMID: 35116572 DOI: 10.21037/tcr-20-2210] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Kim KJ, Lee HW, Seong J. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:1357-65. [PMID: 33217056 DOI: 10.1111/jgh.15319] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
101 Guo W, Zhang C, Qiao T, Zhao J, Shi C. Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy. Front Oncol 2021;11:673199. [PMID: 33996603 DOI: 10.3389/fonc.2021.673199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Fu L, Zhou X, He C. Polymeric Nanosystems for Immunogenic Cell Death-Based Cancer Immunotherapy. Macromol Biosci 2021;21:e2100075. [PMID: 33885225 DOI: 10.1002/mabi.202100075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
103 Vaes RDW, Hendriks LEL, Vooijs M, De Ruysscher D. Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. Cells 2021;10:930. [PMID: 33920544 DOI: 10.3390/cells10040930] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
104 Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Casà C, Di Stefani A, Pagliara MM, D'Aviero A, Schinzari G, Chiesa S, Mazzarella C, Manfrida S, Colloca GF, Marazzi F, Morganti AG, Blasi MA, Peris K, Tortora G, Valentini V. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother 2021;:1-8. [PMID: 33847208 DOI: 10.1080/21645515.2021.1903827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
105 Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, Crittenden M, Shiao S, Khleif S, Gupta S, Formenti SC, Vikram B, Coleman CN, Ahmed MM. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer 2021;9:e002038. [PMID: 33827904 DOI: 10.1136/jitc-2020-002038] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 25.5] [Reference Citation Analysis]
106 Li L, Shi W, Zhou J. Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model. Bioengineered 2021;12:1066-77. [PMID: 33784955 DOI: 10.1080/21655979.2021.1899532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Bilusic M, McMahon S, Madan RA, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marté JL, Floudas C, Strauss J, Redman J, Abdul Sater H, Rabizadeh S, Soon-Shiong P, Schlom J, Gulley JL. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer 2021;9:e002374. [PMID: 33762322 DOI: 10.1136/jitc-2021-002374] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
108 Marcus D, Lieverse RIY, Klein C, Abdollahi A, Lambin P, Dubois LJ, Yaromina A. Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers (Basel) 2021;13:1468. [PMID: 33806808 DOI: 10.3390/cancers13061468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
109 Wang X, Lu J, Guo G, Yu J. Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. Cell Death Dis 2021;12:299. [PMID: 33741903 DOI: 10.1038/s41419-021-03568-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
110 Craig DJ, Nanavaty NS, Devanaboyina M, Stanbery L, Hamouda D, Edelman G, Dworkin L, Nemunaitis JJ. The abscopal effect of radiation therapy. Future Oncol 2021;17:1683-94. [PMID: 33726502 DOI: 10.2217/fon-2020-0994] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
111 de Jong FC, Rutten VC, Zuiverloon TCM, Theodorescu D. Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. Int J Mol Sci 2021;22:2800. [PMID: 33802033 DOI: 10.3390/ijms22062800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
112 DeMaria PJ, Bilusic M, Park DM, Heery CR, Donahue RN, Madan RA, Bagheri MH, Strauss J, Shen V, Marté JL, Steinberg SM, Schlom J, Gilbert MR, Gulley JL. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. Oncologist 2021;26:e847-58. [PMID: 33594772 DOI: 10.1002/onco.13720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
113 Desai R, Coxon AT, Dunn GP. Therapeutic applications of the cancer immunoediting hypothesis. Semin Cancer Biol 2021:S1044-579X(21)00052-3. [PMID: 33711414 DOI: 10.1016/j.semcancer.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
114 Yalamanchali A, Zhang H, Huang KC, Mohan R, Lin SH, Zhu C, Grossman SA, Jin JY, Ellsworth SG. Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies. Adv Radiat Oncol 2021;6:100545. [PMID: 33665481 DOI: 10.1016/j.adro.2020.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
115 Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer 2021;12:2735-46. [PMID: 33854633 DOI: 10.7150/jca.57334] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
116 Uboha NV, Grogan PT, Deming DA. Advances in Immuno-oncology for the Treatment of Colorectal and Anal Cancers. Digestive Disease Interventions 2021;05:070-076. [DOI: 10.1055/s-0040-1722266] [Reference Citation Analysis]
117 Lei H, Shi M, Xu H, Bai S, Xiong X, Wei Q, Yang L. Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations. Cancer Manag Res 2021;13:1719-31. [PMID: 33658847 DOI: 10.2147/CMAR.S288337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Xu Y, Wen N, Sonis ST, Villa A. Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer 2021;127:1796-804. [PMID: 33595843 DOI: 10.1002/cncr.33436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
119 Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Özgüroğlu M, Daniel D, Vicente D, Murakami S, Langer C, Senan S, Spigel D, Rydén A, Zhang Y, O'Brien C, Dennis PA, Antonia SJ. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol 2021;17:1165-84. [PMID: 33583206 DOI: 10.2217/fon-2020-1102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Perna M, Scotti V, Ciammella P, Borghetti P, D'angelo E, Levra NG, Fozza A, Mariotti M, Salvestrini V, Bertolini F, Vagge S, Taraborrelli M, Falcinelli L, Taddeo A, Rossi R, Costantino G, Frassinelli L, Filippi AR, Greco C, Franceschini D, Genovesi D, Lohr F, Magrini SM, Alongi F, Livi L, Bruni A. The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clin Lung Cancer 2021:S1525-7304(21)00028-0. [PMID: 33766477 DOI: 10.1016/j.cllc.2021.02.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
121 Upadhyay R, Venkatesulu BP, Giridhar P, Kim BK, Sharma A, Elghazawy H, Dhanireddy B, Elumalai T, Mallick S, Harkenrider M. Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. Radiother Oncol 2021;157:225-33. [PMID: 33577865 DOI: 10.1016/j.radonc.2021.01.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
122 Greve P, Meyer-wentrup FAG, Peperzak V, Boes M. Upcoming immunotherapeutic combinations for B-cell lymphoma. Immunotherapy Advances 2021;1:ltab001. [DOI: 10.1093/immadv/ltab001] [Reference Citation Analysis]
123 Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA. Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments. Cancers (Basel) 2021;13:678. [PMID: 33567530 DOI: 10.3390/cancers13040678] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
124 Li D, Zhu W, Zhou J, Peng M, Geng Q, Pu X, Wang M, Jiang H. Hypofractionated Low-Dose Radiotherapy Combined with Immune Checkpoint Inhibition in Metastatic Solid Tumors. Onco Targets Ther 2021;14:773-83. [PMID: 33568917 DOI: 10.2147/OTT.S289937] [Reference Citation Analysis]
125 Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. Immune-Checkpoint Blockade Enhances (225)Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. J Nucl Med 2021;62:228-31. [PMID: 32646877 DOI: 10.2967/jnumed.120.246041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
126 Amaldi U, Benedetto E, Damjanovic S, Dosanjh M, Durante M, Georgieva P, Haberer T, Plesko M, Ristova M, Rossi S, Sammut N, Sapinski M, Schopper H, Specht H, Voss R, Vretenar M, Wenninger H. South East European International Institute for Sustainable Technologies (SEEIIST). Front Phys 2021;8. [DOI: 10.3389/fphy.2020.567466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
127 Friedes C, Chakrabarti T, Olson S, Prichett L, Brahmer JR, Forde PM, Voong RK, Marrone KA, Lam VK, Hann CL, Broderick SR, Battafarano RJ, Ha JS, Bush EL, Yang SC, Hales RK, Feliciano JL. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. Lung Cancer 2021;154:36-43. [PMID: 33611224 DOI: 10.1016/j.lungcan.2021.01.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
128 Mattes MD, Eubank TD, Almubarak M, Wen S, Marano GD, Jacobson GM, Ma PC. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer 2021;22:268-73. [PMID: 33608212 DOI: 10.1016/j.cllc.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett 2021;502:84-96. [PMID: 33450360 DOI: 10.1016/j.canlet.2020.12.045] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 16.5] [Reference Citation Analysis]
130 Al-Hadidi SA, Lee HJ. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma. JCO Oncol Pract 2021;17:64-71. [PMID: 33434064 DOI: 10.1200/OP.20.00771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Kandalaft LE, Odunsi K, Coukos G. Immune Therapy Opportunities in Ovarian Cancer. Am Soc Clin Oncol Educ Book 2020;40:1-13. [PMID: 32412818 DOI: 10.1200/EDBK_280539] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
132 Azghadi S, Daly ME. Radiation and immunotherapy combinations in non-small cell lung cancer. Cancer Treat Res Commun 2021;26:100298. [PMID: 33387868 DOI: 10.1016/j.ctarc.2020.100298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
133 Padmanabhan R, Meskin N, Moustafa AA. Control Strategies for Cancer Therapy. Series in BioEngineering 2021. [DOI: 10.1007/978-981-15-8640-8_10] [Reference Citation Analysis]
134 Zarnani A, Jafari D, Bozorgmehr M, Shabani M, Barzegar-yarmohammadi L, Ghaemimanesh F, Jeddi-tehrani M. Monoclonal Antibodies for Cancer Immunotherapy. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_15] [Reference Citation Analysis]
135 Huang SH, Pilar A, Li J, Xu Z, O’sullivan B. Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Critical Issues in Head and Neck Oncology 2021. [DOI: 10.1007/978-3-030-63234-2_9] [Reference Citation Analysis]
136 Gribkova IV, Zavyalov A. Multiple Myeloma and Dendritic Cell Vaccines. Клиническая онкогематология 2021;14:370-377. [DOI: 10.21320/2500-2139-2021-14-3-370-377] [Reference Citation Analysis]
137 Kim N, Myoung Noh J, Lee W, Park B, Park H, Young Park J, Pyo H. Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy. Radiother Oncol 2021;156:166-73. [PMID: 33359267 DOI: 10.1016/j.radonc.2020.12.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
138 Mireştean CC, Crişan A, Buzea C, Iancu RI, Iancu DT. Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes-"Immunological Dose Painting". Medicina (Kaunas) 2020;57:6. [PMID: 33374739 DOI: 10.3390/medicina57010006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Valentinuzzi D, Jeraj R. Computational modelling of modern cancer immunotherapy. Phys Med Biol 2020;65:24TR01. [PMID: 33091898 DOI: 10.1088/1361-6560/abc3fc] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
140 Hagan CT 4th, Mi Y, Knape NM, Wang AZ. Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. Bioconjug Chem 2020;31:2668-78. [PMID: 33251789 DOI: 10.1021/acs.bioconjchem.0c00520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
141 Franzoi MA, Romano E, Piccart M. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol 2021;32:323-36. [PMID: 33307202 DOI: 10.1016/j.annonc.2020.11.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
142 Peyraga G, Ducassou A, Arnaud FX, Lizée T, Pouédras J, Moyal É. [Radiotherapy and spinal toxicity: News and perspectives]. Cancer Radiother 2021;25:55-61. [PMID: 33303351 DOI: 10.1016/j.canrad.2020.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 De Felice F, Giudice E, Bolomini G, Distefano MG, Scambia G, Fagotti A, Marchetti C. Pembrolizumab for advanced cervical cancer: safety and efficacy. Expert Rev Anticancer Ther 2021;21:221-8. [PMID: 33183120 DOI: 10.1080/14737140.2021.1850279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
144 Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer 2021;151:30-8. [PMID: 33285469 DOI: 10.1016/j.lungcan.2020.11.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
145 Guo T, Zou L, Ni J, Chu X, Zhu Z. Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy. Transl Lung Cancer Res 2020;9:2097-112. [PMID: 33209629 DOI: 10.21037/tlcr-20-511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
146 Pohanková D, Kopecký J. Radiotherapy and immunotherapy are irreplaceable in the treatment of cancer. Onkologie 2020;14:213-218. [DOI: 10.36290/xon.2020.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Xu P, Liang F. Nanomaterial-Based Tumor Photothermal Immunotherapy. Int J Nanomedicine 2020;15:9159-80. [PMID: 33244232 DOI: 10.2147/IJN.S249252] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
148 Shen LF, Zhou SH, Guo Y. Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer. Onco Targets Ther 2020;13:11221-35. [PMID: 33173312 DOI: 10.2147/OTT.S269767] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
149 Washah HN, Salifu EY, Soremekun O, Elrashedy AA, Munsamy G, Olotu FA, Soliman ME. Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives. CCHTS 2020;23:687-98. [DOI: 10.2174/1386207323666200427113734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
150 Kumari S, Mukherjee S, Sinha D, Abdisalaam S, Krishnan S, Asaithamby A. Immunomodulatory Effects of Radiotherapy. Int J Mol Sci 2020;21:E8151. [PMID: 33142765 DOI: 10.3390/ijms21218151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
151 Oertel M, Elsayad K, Engenhart-Cabillic R, Reinartz G, Baues C, Schmidberger H, Vordermark D, Marnitz S, Lukas P, Ruebe C, Engert A, Lenz G, Eich HT. Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. Strahlenther Onkol. 2020;196:1096-1102. [PMID: 33125504 DOI: 10.1007/s00066-020-01705-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
152 Nimmagadda S. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers (Basel) 2020;12:E3173. [PMID: 33137949 DOI: 10.3390/cancers12113173] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
153 Tinganelli W, Durante M. Carbon Ion Radiobiology. Cancers (Basel) 2020;12:E3022. [PMID: 33080914 DOI: 10.3390/cancers12103022] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 20.3] [Reference Citation Analysis]
154 Matsui Y. Current Multimodality Treatments Against Brain Metastases from Renal Cell Carcinoma. Cancers (Basel) 2020;12:E2875. [PMID: 33036276 DOI: 10.3390/cancers12102875] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
155 Xu H, Lin M, Hu Y, Zhang L, Li Q, Zhu J, Wang S, Xi M. Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes. Oncologist 2021;26:e425-34. [PMID: 32960471 DOI: 10.1002/onco.13533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
156 Issels RD, Lindner LH, von Bergwelt-Baildon M, Lang P, Rischpler C, Diem H, Mosetter B, Eckl J, Schendel DJ, Salat C, Stötzer O, Burdach S, von Luettichau-Teichert I, Handgretinger R, Neumann J, Kirchner T, Steiger K, Boxberg M, Mansmann U, Multhoff G, Noessner E. Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case report. Int J Hyperthermia 2020;37:55-65. [PMID: 31918587 DOI: 10.1080/02656736.2019.1709666] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
157 Li S, Chu X, Ye L, Ni J, Zhu Z. A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. Transl Lung Cancer Res 2020;9:2082-96. [PMID: 33209628 DOI: 10.21037/tlcr-20-512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
158 Zhao X, Shao C. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade. Cancers (Basel) 2020;12:E2762. [PMID: 32992835 DOI: 10.3390/cancers12102762] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
159 Tholomier C, Marcq G, Shinde-jadhav S, Ayoub M, Huang JM, Kool R, Skowronski R, Brimo F, Mansure JJ, Kassouf W. Optimizing Sequence of PD-L1 Immune-Checkpoint Inhibitors and Radiation Therapy in Bladder Cancer. BLC 2020;6:295-302. [DOI: 10.3233/blc-200315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Nielsen S, Bassler N, Grzanka L, Swakon J, Olko P, Horsman MR, Sørensen BS. Proton scanning and X-ray beam irradiation induce distinct regulation of inflammatory cytokines in a preclinical mouse model. Int J Radiat Biol 2020;96:1238-44. [PMID: 32780616 DOI: 10.1080/09553002.2020.1807644] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
161 Lin CH, Chou WC, Wu YY, Lin CY, Chang KP, Liao CT, Ho TY, Yeh CM, Liu CJ, Hung SP, Lee CH, Chen PJ, Chou YC, Fan KH, Huang BS, Tung-Chieh Chang J, Wang CC, Tsang NM. Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study. Radiother Oncol 2021;154:76-86. [PMID: 32941957 DOI: 10.1016/j.radonc.2020.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Milhem C, Moralès O, Ingelaere C, Pasquier D, Mordon S, Mortier L, Mirabel X, Delhem N. Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient. Int J Mol Sci 2020;21:E6772. [PMID: 32942768 DOI: 10.3390/ijms21186772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
163 Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun 2020;11:4591. [PMID: 32929084 DOI: 10.1038/s41467-020-18245-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
164 Osei E, Francis R, Sheraz L. A review of radiation induced abscopal effect: combining radiotherapy and immunotherapy to treat the untreated distant metastatic tumours. J Radiother Pract 2022;21:117-24. [DOI: 10.1017/s1460396920000680] [Reference Citation Analysis]
165 Attia CG, Fei N, Almubarak M, Ma PC, Mattes MD. Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer. J Med Imaging Radiat Oncol 2020;64:866-72. [PMID: 32881332 DOI: 10.1111/1754-9485.13096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Jiang C, Wallington DG, Anker CJ, Lawson DH, Yushak ML, Kudchadkar RR, Tarhini A, Khan MK. Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. Neurosurgery 2020;87:498-515. [PMID: 32315430 DOI: 10.1093/neuros/nyaa076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 O'Cathail SM, Smith T, Owens R, Zeniou A, Tsang Y, Holyoake DLP, Murray L, Harrison M, Hawkins MA. Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiother Oncol 2020;151:280-6. [PMID: 32866563 DOI: 10.1016/j.radonc.2020.08.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
168 Zeng F, Qin H, Liu L, Chang H, Chen Q, Wu L, Zhang L, Wu Z, Xing D. Photoacoustic-immune therapy with a multi-purpose black phosphorus-based nanoparticle. Nano Res 2020;:1-13. [PMID: 32904446 DOI: 10.1007/s12274-020-3028-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
169 Yang S, Liu XL, Guo XL, Song B, Li SZ, Sun XF, Feng Y. Solitary metastasis to the skin and colon from gastric cancer after curative gastrectomy and chemotherapy: A case report. Medicine (Baltimore) 2020;99:e21532. [PMID: 32756202 DOI: 10.1097/MD.0000000000021532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
170 Chen JL, Pan CK, Huang YS, Tsai CY, Wang CW, Lin YL, Kuo SH, Shieh MJ. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunol Immunother 2021;70:391-404. [PMID: 32761424 DOI: 10.1007/s00262-020-02690-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
171 Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662-80. [PMID: 32753728 DOI: 10.1038/s41568-020-0285-7] [Cited by in Crossref: 370] [Cited by in F6Publishing: 404] [Article Influence: 123.3] [Reference Citation Analysis]
172 Zhou Z, Zhao J, Hu K, Hou X, Sun X, Pan X, Wang X, Li N, Yang Z, Zhang F, Zhou Q, Zhan L. Single High-Dose Radiation Enhances Dendritic Cell Homing and T Cell Priming by Promoting Reactive Oxygen Species-Induced Cytoskeletal Reorganization. Int J Radiat Oncol Biol Phys 2021;109:95-108. [PMID: 32763455 DOI: 10.1016/j.ijrobp.2020.07.2321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
173 Cao Y, Li W, Wang Z, Pang H. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. Tumori 2021;107:282-91. [PMID: 32734832 DOI: 10.1177/0300891620940382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
174 Wang B, Sun L, Yuan Z, Tao Z. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. Med Oncol 2020;37:66. [PMID: 32696094 DOI: 10.1007/s12032-020-01390-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
175 Haeger A, Alexander S, Vullings M, Kaiser FMP, Veelken C, Flucke U, Koehl GE, Hirschberg M, Flentje M, Hoffman RM, Geissler EK, Kissler S, Friedl P. Collective cancer invasion forms an integrin-dependent radioresistant niche. J Exp Med 2020;217:e20181184. [PMID: 31658985 DOI: 10.1084/jem.20181184] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
176 Yan BD, Cong XF, Zhao SS, Ren M, Liu ZL, Li Z, Chen C, Yang L. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. Curr Cancer Drug Targets 2019;19:199-209. [PMID: 29714142 DOI: 10.2174/1568009618666180430124738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, Giaccone G. Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer 2020;8:e000980. [PMID: 32616557 DOI: 10.1136/jitc-2020-000980] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
178 Chen J, Liu X, Zeng Z, Li J, Luo Y, Sun W, Gong Y, Zhang J, Wu Q, Xie C. Immunomodulation of NK Cells by Ionizing Radiation. Front Oncol 2020;10:874. [PMID: 32612950 DOI: 10.3389/fonc.2020.00874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
179 Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst 2019;111:1131-41. [PMID: 31322663 DOI: 10.1093/jnci/djz093] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 24.0] [Reference Citation Analysis]
180 Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clin Lung Cancer 2021;22:e425-30. [PMID: 32778511 DOI: 10.1016/j.cllc.2020.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
181 Chua CYX, Ho J, Demaria S, Ferrari M, Grattoni A. Emerging Technologies for Local Cancer Treatment. Adv Therap 2020;3:2000027. [DOI: 10.1002/adtp.202000027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
182 López Alfonso JC, Poleszczuk J, Walker R, Kim S, Pilon-Thomas S, Conejo-Garcia JJ, Soliman H, Czerniecki B, Harrison LB, Enderling H. Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. JCO Clin Cancer Inform 2019;3:1-16. [PMID: 30964698 DOI: 10.1200/CCI.18.00075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
183 Donini M, Buti S, Massari F, Mollica V, Rizzo A, Montironi R, Bersanelli M, Santoni M. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert Rev Anticancer Ther 2020;20:491-501. [PMID: 32479120 DOI: 10.1080/14737140.2020.1770601] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
184 Desideri I, Salvestrini V, Livi L. Recent advances in de-intensification of radiotherapy in elderly cancer patients. F1000Res 2020;9:F1000 Faculty Rev-447. [PMID: 32518630 DOI: 10.12688/f1000research.21151.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
185 Pan S, Wang J, Wu A, Guo Z, Wang Z, Zheng L, Dai Y, Zhu L, Nie J, Hei TK, Zhou G, Li Y, Li B, Hu W. Radiation Exposure-Induced Changes in the Immune Cells and Immune Factors of Mice With or Without Primary Lung Tumor. Dose Response 2020;18:1559325820926744. [PMID: 32489339 DOI: 10.1177/1559325820926744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
186 Vogelius IR, Petersen J, Bentzen SM. Harnessing data science to advance radiation oncology. Mol Oncol 2020;14:1514-28. [PMID: 32255249 DOI: 10.1002/1878-0261.12685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
187 Singh MP, Sethuraman SN, Ritchey J, Fiering S, Guha C, Malayer J, Ranjan A. In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma. Int J Hyperthermia 2019;36:64-73. [PMID: 31795832 DOI: 10.1080/02656736.2019.1663280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
188 Mirabile A, Rivoltini L, Daveri E, Vernieri C, Mele R, Porcu L, Lazzari C, Bulotta A, Viganò MG, Cascinu S, Gregorc V. Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers (Basel) 2020;12:E1153. [PMID: 32375310 DOI: 10.3390/cancers12051153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
189 Kim D, Kim JM, Kim JS, Kim S, Kim KH. Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. J Clin Med 2020;9:E1265. [PMID: 32349330 DOI: 10.3390/jcm9051265] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
190 Estrade F, Lescure C, Muzellec L, Pedrono M, Palard X, Pracht M, Le Sourd S, Rolland Y, Uguen T, Garin E, Edeline J. Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. Cardiovasc Intervent Radiol 2020;43:1175-81. [PMID: 32342156 DOI: 10.1007/s00270-020-02467-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
191 Labbozzetta M, Notarbartolo M, Poma P. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. Int J Mol Sci 2020;21:E3070. [PMID: 32349210 DOI: 10.3390/ijms21093070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
192 Roscher M, Bakos G, Benešová M. Atomic Nanogenerators in Targeted Alpha Therapies: Curie's Legacy in Modern Cancer Management. Pharmaceuticals (Basel) 2020;13:E76. [PMID: 32340103 DOI: 10.3390/ph13040076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
193 Verma V, Haque W, Cushman TR, Lin C, Simone CB 2nd, Chang JY, McClelland S 3rd, Welsh JW. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother 2019;42:55-64. [PMID: 30628924 DOI: 10.1097/CJI.0000000000000253] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
194 Holub K, Vargas A, Biete A. Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients. Clin Transl Oncol 2020;22:2040-8. [PMID: 32285291 DOI: 10.1007/s12094-020-02345-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
195 Chen M, Qiao G, Hylander BL, Mohammadpour H, Wang XY, Subjeck JR, Singh AK, Repasky EA. Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation. Nat Commun 2020;11:1821. [PMID: 32286326 DOI: 10.1038/s41467-020-15676-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
196 Fellinger H, Stangl S, Hernandez Schnelzer A, Schwab M, Di Genio T, Pieper M, Werner C, Shevtsov M, Haller B, Multhoff G. Time- and Dose-Dependent Effects of Ionizing Irradiation on the Membrane Expression of Hsp70 on Glioma Cells. Cells 2020;9:E912. [PMID: 32276468 DOI: 10.3390/cells9040912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
197 Hagemann UB, Wickstroem K, Hammer S, Bjerke RM, Zitzmann-Kolbe S, Ryan OB, Karlsson J, Scholz A, Hennekes H, Mumberg D, Cuthbertson AS. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy. Cancer Biother Radiopharm 2020;35:497-510. [PMID: 32255671 DOI: 10.1089/cbr.2020.3568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
198 Punnanitinont A, Kannisto ED, Matsuzaki J, Odunsi K, Yendamuri S, Singh AK, Patnaik SK. Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells. Int J Mol Sci 2020;21:E2573. [PMID: 32272797 DOI: 10.3390/ijms21072573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
199 Abdou P, Wang Z, Chen Q, Chan A, Zhou DR, Gunadhi V, Gu Z. Advances in engineering local drug delivery systems for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2020;12:e1632. [PMID: 32255276 DOI: 10.1002/wnan.1632] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
200 Kleinberg L, Sloan L, Grossman S, Lim M. Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy. Neurosurgery 2019;85:441-53. [PMID: 31232425 DOI: 10.1093/neuros/nyz198] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
201 Weenink B, French PJ, Sillevis Smitt PAE, Debets R, Geurts M. Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers (Basel) 2020;12:E751. [PMID: 32235752 DOI: 10.3390/cancers12030751] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
202 Ellerin BE, Demandante CGN, Martins JT. Pure abscopal effect of radiotherapy in a salivary gland carcinoma: Case report, literature review, and a search for new approaches. Cancer Radiother 2020;24:226-46. [PMID: 32192840 DOI: 10.1016/j.canrad.2020.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
203 Mondini M, Levy A, Meziani L, Milliat F, Deutsch E. Radiotherapy-immunotherapy combinations - perspectives and challenges. Mol Oncol 2020;14:1529-37. [PMID: 32112478 DOI: 10.1002/1878-0261.12658] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
204 MacManus MP, Hofman MS, Hicks RJ, Campbell BA, Wirth A, Seymour JF, Haynes N, Burbury K. Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. Int J Radiat Oncol Biol Phys 2020;108:204-11. [PMID: 32151671 DOI: 10.1016/j.ijrobp.2020.02.636] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
205 Wallington DG, Rashid AS, Buchwald ZS, Sudmeier LJ, Khan MK. Complete and Durable Response After Radiation Therapy to Primary Tumor Site of a Patient With Metastatic Anorectal Mucosal Melanoma With Oligoprogression on Nivolumab. Adv Radiat Oncol 2020;5:503-10. [PMID: 32529147 DOI: 10.1016/j.adro.2020.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
206 Remic T, Sersa G, Ursic K, Cemazar M, Kamensek U. Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant. Vaccines (Basel) 2020;8:E111. [PMID: 32121641 DOI: 10.3390/vaccines8010111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
207 Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol 2020;93:20200042. [PMID: 32101479 DOI: 10.1259/bjr.20200042] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
208 Daniel Grass G, Alfonso JC, Welsh E, Ahmed KA, Teer JK, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-roca JF. Harnessing tumor immune ecosystem dynamics to personalize radiotherapy.. [DOI: 10.1101/2020.02.11.944512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
209 Wrona A. Role of immunotherapy in stage III nonsmall cell lung cancer. Curr Opin Oncol 2019;31:18-23. [PMID: 30489337 DOI: 10.1097/CCO.0000000000000493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
210 Alfonso JCL, Papaxenopoulou LA, Mascheroni P, Meyer-Hermann M, Hatzikirou H. On the Immunological Consequences of Conventionally Fractionated Radiotherapy. iScience 2020;23:100897. [PMID: 32092699 DOI: 10.1016/j.isci.2020.100897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
211 Montaseri G, Alfonso JCL, Hatzikirou H, Meyer-Hermann M. A minimal modeling framework of radiation and immune system synergy to assist radiotherapy planning. J Theor Biol 2020;486:110099. [PMID: 31790681 DOI: 10.1016/j.jtbi.2019.110099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Galon J, Bruni D. Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity 2020;52:55-81. [PMID: 31940273 DOI: 10.1016/j.immuni.2019.12.018] [Cited by in Crossref: 211] [Cited by in F6Publishing: 182] [Article Influence: 70.3] [Reference Citation Analysis]
213 Zhou S, Yang H, Zhang J, Wang J, Liang Z, Liu S, Li Y, Pan Y, Zhao L, Xi M. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2020;108:286-94. [PMID: 32004580 DOI: 10.1016/j.ijrobp.2020.01.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
214 Zhao Q, Li T, Chen G, Zeng Z, He J. Prognosis and Risk Factors of Radiation-Induced Lymphopenia in Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy. Front Oncol 2019;9:1488. [PMID: 32039000 DOI: 10.3389/fonc.2019.01488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
215 Tian S, Switchenko JM, Buchwald ZS, Patel PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera M, Curran WJ, Higgins KA. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108:304-313. [PMID: 31982496 DOI: 10.1016/j.ijrobp.2019.12.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
216 de Ruiter EJ, de Roest RH, Brakenhoff RH, Leemans CR, de Bree R, Terhaard CHJ, Willems SM. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors. Cancer Immunol Immunother 2020;69:581-91. [PMID: 31980916 DOI: 10.1007/s00262-020-02481-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
217 Taguchi A, Furusawa A, Ito K, Nakajima Y, Shimizuguchi T, Hara K, Takao M, Kashiyama T, Kino N, Karasawa K, Yasugi T. Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study. Int J Clin Oncol 2020;25:955-62. [PMID: 31960184 DOI: 10.1007/s10147-020-01623-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
218 Igaz N, Szőke K, Kovács D, Buhala A, Varga Z, Bélteky P, Rázga Z, Tiszlavicz L, Vizler C, Hideghéty K, Kónya Z, Kiricsi M. Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. Nanomaterials 2020;10:158. [DOI: 10.3390/nano10010158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
219 Kirstein MM, Wirth TC. Multimodale Therapie des hepatozellulären Karzinoms. Internist 2020;61:164-9. [DOI: 10.1007/s00108-019-00722-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
220 Hori K, Hirohashi Y, Aoyagi T, Taniguchi N, Murakumo M, Miyata H, Torigoe T, Abe T, Shinohara N, Morita K. Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report. Exp Ther Med 2020;19:1903-7. [PMID: 32104247 DOI: 10.3892/etm.2020.8423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
221 Aryan Z, Keshavarz-fathi M, Mellstedt H, Rezaei N. Cancer Immunotherapy Confers a Global Benefit. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_1] [Reference Citation Analysis]
222 Kabacaoglu D, Ruess DA, Algül H. Targeting the Immune System in Pancreatic Cancer. Translational Pancreatic Cancer Research 2020. [DOI: 10.1007/978-3-030-49476-6_14] [Reference Citation Analysis]
223 Grass GD, Lopez Alfonso JC, Welsh E, Ahmed KA, Teer JK, Harrison LB, Cleveland JL, Mule JJ, Eschrich SA, Enderling H, Torres-roca J. Harnessing Tumor Immune Ecosystem Dynamics to Personalize Radiation Therapy. SSRN Journal. [DOI: 10.2139/ssrn.3581358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
224 Stephen B, Hajjar J. Overview of Basic Immunology and Clinical Application. Adv Exp Med Biol 2020;1244:1-36. [PMID: 32301008 DOI: 10.1007/978-3-030-41008-7_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
225 Eu D, Hosni A, Spreafico A, Irish J. Combination therapy and outcomes in head and neck cancer. Novel Therapies in Head and Neck Cancer: Beyond the Horizon 2020. [DOI: 10.1016/b978-0-12-820679-9.00009-8] [Reference Citation Analysis]
226 Buti S, Bersanelli M, Viansone A, Leonetti A, Masini C, Ratta R, Procopio G, Maines F, Iacovelli R, Ciccarese C, Vitale MG, De Giorgi U, Mucciarini C, Maruzzo M, Prati G, Lattanzi E, Ciammella P, Bruni A, Andreani S, D'abbiero N. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Cancer Treatment and Research Communications 2020;22:100161. [DOI: 10.1016/j.ctarc.2019.100161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
227 Gorbet MJ, Ranjan A. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. Pharmacol Ther 2020;207:107456. [PMID: 31863820 DOI: 10.1016/j.pharmthera.2019.107456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
228 Bersanelli M, Lattanzi E, D'Abbiero N, Buti S, Leonetti A, Canè MG, Trapani S, Gravina G, Porzio G, Cannita K, Marino PD, Grassadonia A, Tinari N, Tursi M, Giaiacopi E, Michiara M, Bordi P, Perrone F, Caravatta L, Trignani M, Genovesi D, Natoli C, Ficorella C, Tiseo M, Cortellini A. Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. Biomed Rep 2020;12:59-67. [PMID: 31929875 DOI: 10.3892/br.2019.1265] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
229 Bravatà V, Cammarata FP, Minafra L, Musso R, Pucci G, Spada M, Fazio I, Russo G, Forte GI. Gene Expression Profiles Induced by High-dose Ionizing Radiation in MDA-MB-231 Triple-negative Breast Cancer Cell Line. Cancer Genomics Proteomics 2019;16:257-66. [PMID: 31243106 DOI: 10.21873/cgp.20130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
230 D’andrea MA, Reddy GK. Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy. American Journal of Clinical Oncology 2020;43:218-28. [DOI: 10.1097/coc.0000000000000651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
231 Liao NC, Shih YL, Ho MT, Lu TJ, Lee CH, Peng SF, Leu SJ, Chung JG. Cardamonin induces immune responses and enhances survival rate in WEHI-3 cell-generated mouse leukemia in vivo. Environ Toxicol 2020;35:457-67. [PMID: 31793136 DOI: 10.1002/tox.22881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
232 Li Q, Xiao Y. Bifurcation analyses and hormetic effects of a discrete-time tumor model. Applied Mathematics and Computation 2019;363:124618. [DOI: 10.1016/j.amc.2019.124618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
233 Bidram E, Esmaeili Y, Ranji-burachaloo H, Al-zaubai N, Zarrabi A, Stewart A, Dunstan DE. A concise review on cancer treatment methods and delivery systems. Journal of Drug Delivery Science and Technology 2019;54:101350. [DOI: 10.1016/j.jddst.2019.101350] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
234 Sun X, Gan L, Na A, Ge L, Chen B, Liu J. Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer. J Oncol 2019;2019:1483406. [PMID: 31871454 DOI: 10.1155/2019/1483406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
235 Cherukula K, Park MS, Sontyana AG, Mathew AP, Vijayan V, Bae WK, Park IK. Role of Immunosuppressive Microenvironment in Acquiring Immunotolerance Post-Photothermal Therapy. J Korean Med Sci 2019;34:e272. [PMID: 31726492 DOI: 10.3346/jkms.2019.34.e272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
236 Woods K, Neph R, Nguyen D, Sheng K. A sparse orthogonal collimator for small animal intensity-modulated radiation therapy. Part II: hardware development and commissioning. Med Phys 2019;46:5733-47. [PMID: 31621091 DOI: 10.1002/mp.13870] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
237 Sridharan V, Schoenfeld JD. Immunotherapy and Radiation: Charting a Path Forward Together. Hematol Oncol Clin North Am 2019;33:1057-69. [PMID: 31668206 DOI: 10.1016/j.hoc.2019.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
238 Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine 2019;49:96-105. [PMID: 31676387 DOI: 10.1016/j.ebiom.2019.10.032] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
239 Huang W, Fan Y, Cheng X, Liang H, Pan H, Xiao T, Chen M, Guan J. A preliminary Study on the Effect of Head and Neck Chemoradiotherapy on Systematic Immunity. Dose Response 2019;17:1559325819884186. [PMID: 31695581 DOI: 10.1177/1559325819884186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
240 Zhang HG, Yang P, Jiang T, Zhang JY, Jin XJ, Hu Y, Sun J, Du SS, Zeng ZC. Lymphopenia Is Associated with Gross Target Volumes and Fractions in Hepatocellular Carcinoma Patients Treated with External Beam Radiation Therapy and Also Indicates Worse Overall Survival. Can J Gastroenterol Hepatol 2019;2019:9691067. [PMID: 31781521 DOI: 10.1155/2019/9691067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
241 Dünker N, Jendrossek V. Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research. Cancers (Basel) 2019;11:E1499. [PMID: 31591362 DOI: 10.3390/cancers11101499] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
242 Buti S, Leonetti A, Lattanzi E, D'Abbiero N, Bersanelli M. Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches". Ann Transl Med 2019;7:S106. [PMID: 31576313 DOI: 10.21037/atm.2019.05.04] [Reference Citation Analysis]
243 Hlavata Z, Solinas C, De Silva P, Porcu M, Saba L, Willard-Gallo K, Scartozzi M. The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity? Target Oncol 2018;13:113-23. [PMID: 29470785 DOI: 10.1007/s11523-018-0556-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
244 Wang S, Yang L, Cho HY, Dean Chueng ST, Zhang H, Zhang Q, Lee KB. Programmed degradation of a hierarchical nanoparticle with redox and light responsivity for self-activated photo-chemical enhanced chemodynamic therapy. Biomaterials 2019;224:119498. [PMID: 31557590 DOI: 10.1016/j.biomaterials.2019.119498] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
245 Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, Current, and Future of Immunotherapies for Prostate Cancer.Front Oncol. 2019;9:884. [PMID: 31572678 DOI: 10.3389/fonc.2019.00884] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 14.3] [Reference Citation Analysis]
246 Batty CJ, Tiet P, Bachelder EM, Ainslie KM. Drug Delivery for Cancer Immunotherapy and Vaccines. Pharm Nanotechnol 2018;6:232-44. [PMID: 30227827 DOI: 10.2174/2211738506666180918122337] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
247 Bang A, Schoenfeld JD, Sun AY. PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2019;8:S139-46. [PMID: 31673518 DOI: 10.21037/tlcr.2019.09.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
248 Cho Y, Park S, Byun HK, Lee CG, Cho J, Hong MH, Kim HR, Cho BC, Kim S, Park J, Yoon HI. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2019;105:1065-73. [PMID: 31476418 DOI: 10.1016/j.ijrobp.2019.08.047] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 12.5] [Reference Citation Analysis]
249 Kent MS, Emami S, Rebhun R, Theon A, Hansen K, Sparger E. The effects of local irradiation on circulating lymphocytes in dogs receiving fractionated radiotherapy. Vet Comp Oncol 2020;18:191-8. [PMID: 31424596 DOI: 10.1111/vco.12531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
250 Dong Z, Yang Z, Hao Y, Feng L. Fabrication of H2O2-driven nanoreactors for innovative cancer treatments. Nanoscale 2019;11:16164-86. [PMID: 31453999 DOI: 10.1039/c9nr04418c] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
251 Goto T. Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. Vaccines (Basel) 2019;7:E100. [PMID: 31455032 DOI: 10.3390/vaccines7030100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
252 Ngwa W. Systemic immune effects boost radiotherapy. Nat Biomed Eng 2018;2:562-3. [PMID: 31015632 DOI: 10.1038/s41551-018-0264-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
253 Gjyshi O, Liao Z. Proton therapy for locally advanced non-small cell lung cancer. Br J Radiol 2020;93:20190378. [PMID: 31430188 DOI: 10.1259/bjr.20190378] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
254 Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in Ovarian Cancer: Are We There Yet? J Clin Oncol 2019;37:2460-71. [PMID: 31403857 DOI: 10.1200/JCO.19.00508] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
255 Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol 2019;5:1205-14. [PMID: 30973611 DOI: 10.1001/jamaoncol.2018.7147] [Cited by in Crossref: 171] [Cited by in F6Publishing: 181] [Article Influence: 42.8] [Reference Citation Analysis]
256 Durante M, Formenti S. Harnessing radiation to improve immunotherapy: better with particles? Br J Radiol 2020;93:20190224. [PMID: 31317768 DOI: 10.1259/bjr.20190224] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
257 Casesnoves F. Improvements in Simulations for Radiotherapy Wedge Filter dose and AAA-Convolution Factor Algorithms. IJSRSET 2019. [DOI: 10.32628/ijsrset196381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
258 Otter SJ, Chatterjee J, Stewart AJ, Michael A. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer. Clin Oncol (R Coll Radiol) 2019;31:834-43. [PMID: 31331818 DOI: 10.1016/j.clon.2019.07.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
259 Kamatham S, Shahjehan F, Kasi PM. Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions. Curr Colorectal Cancer Rep 2019;15:112-21. [DOI: 10.1007/s11888-019-00437-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
260 Jarosz-Biej M, Smolarczyk R, Cichoń T, Kułach N. Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy. Int J Mol Sci 2019;20:E3212. [PMID: 31261963 DOI: 10.3390/ijms20133212] [Cited by in Crossref: 138] [Cited by in F6Publishing: 152] [Article Influence: 34.5] [Reference Citation Analysis]
261 Cogdill AP, Gaudreau PO, Arora R, Gopalakrishnan V, Wargo JA. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol 2018;39:900-20. [PMID: 30392721 DOI: 10.1016/j.it.2018.09.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
262 Jain NA, Otterson GA. Immunotherapy in inoperable stage III non-small cell lung cancer: a review. Drugs Context 2019;8:212578. [PMID: 31258616 DOI: 10.7573/dic.212578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
263 Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 2019;105:346-55. [PMID: 31175902 DOI: 10.1016/j.ijrobp.2019.05.064] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
264 Patel VG, Oh WK. The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy 2019;11:903-12. [PMID: 31161846 DOI: 10.2217/imt-2019-0019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
265 Katz SC, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, Wang LJ, Armenio V, Espat NJ, Junghans RP. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther 2020;27:341-55. [PMID: 31155611 DOI: 10.1038/s41417-019-0104-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
266 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 57] [Article Influence: 14.3] [Reference Citation Analysis]
267 de Forceville L, Deau-Fischer B, Franchi P, Arsène-Henry A, Cassou Mounat T, Bouscary D, Kirova YM. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases. Cancer Radiother 2019;23:232-9. [PMID: 31147173 DOI: 10.1016/j.canrad.2018.12.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
268 Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol 2018;15:477-94. [PMID: 29872177 DOI: 10.1038/s41571-018-0046-7] [Cited by in Crossref: 136] [Cited by in F6Publishing: 148] [Article Influence: 34.0] [Reference Citation Analysis]
269 Bang A, Dawson LA. Radiotherapy for HCC: Ready for prime time? JHEP Rep 2019;1:131-7. [PMID: 32039361 DOI: 10.1016/j.jhepr.2019.05.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
270 Trommer M, Yeo SY, Persigehl T, Bunck A, Grüll H, Schlaak M, Theurich S, von Bergwelt-Baildon M, Morgenthaler J, Herter JM, Celik E, Marnitz S, Baues C. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. Front Pharmacol 2019;10:511. [PMID: 31156434 DOI: 10.3389/fphar.2019.00511] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
271 Li Q, Zhou S, Liu S, Liu S, Yang H, Zhao L, Liu M, Hu Y, Xi M. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy. Ann Surg Oncol 2019;26:2882-9. [DOI: 10.1245/s10434-019-07334-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
272 Osipov A, Murphy A, Zheng L. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Adv Cancer Res 2019;143:63-144. [PMID: 31202363 DOI: 10.1016/bs.acr.2019.03.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
273 Yildirim BA, Guler OC, Kose F, Onal C. The prognostic value of haematologic parameter changes during treatment in cervical cancer patients treated with definitive chemoradiotherapy. J Obstet Gynaecol 2019;39:695-701. [PMID: 31023114 DOI: 10.1080/01443615.2019.1586852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
274 Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol 2019;12:42. [PMID: 31014381 DOI: 10.1186/s13045-019-0730-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
275 George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer 2019;125:2732-46. [PMID: 31017664 DOI: 10.1002/cncr.32150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
276 Ehlerding EB, Lee HJ, Barnhart TE, Jiang D, Kang L, McNeel DG, Engle JW, Cai W. Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with 89Zr-Df-Atezolizumab. Bioconjug Chem 2019;30:1434-41. [PMID: 30973703 DOI: 10.1021/acs.bioconjchem.9b00178] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
277 ElJalby M, Pannullo SC, Schwartz TH, Parashar B, Wernicke AG. Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases. World Neurosurg 2019;127:397-404. [PMID: 31004856 DOI: 10.1016/j.wneu.2019.04.093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
278 Stephens SJ, Moravan MJ, Salama JK. Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer. J Oncol Pract 2018;14:23-31. [PMID: 29324212 DOI: 10.1200/JOP.2017.026500] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
279 Spring BQ, Lang RT, Kercher EM, Rizvi I, Wenham RM, Conejo-Garcia JR, Hasan T, Gatenby RA, Enderling H. Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. Front Phys 2019;7:46. [PMID: 31123672 DOI: 10.3389/fphy.2019.00046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
280 Ostrand-Rosenberg S, Horn LA, Ciavattone NG. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy. Front Oncol 2019;9:215. [PMID: 31001479 DOI: 10.3389/fonc.2019.00215] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
281 DuRoss AN, Neufeld MJ, Rana S, Thomas CR Jr, Sun C. Integrating nanomedicine into clinical radiotherapy regimens. Adv Drug Deliv Rev 2019;144:35-56. [PMID: 31279729 DOI: 10.1016/j.addr.2019.07.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
282 Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;452:66-70. [PMID: 30902563 DOI: 10.1016/j.canlet.2019.02.048] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 15.3] [Reference Citation Analysis]
283 Eckert F, Zwirner K, Boeke S, Thorwarth D, Zips D, Huber SM. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. Front Immunol 2019;10:407. [PMID: 30930892 DOI: 10.3389/fimmu.2019.00407] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
284 Ashcraft KA, Warner AB, Jones LW, Dewhirst MW. Exercise as Adjunct Therapy in Cancer. Semin Radiat Oncol 2019;29:16-24. [PMID: 30573180 DOI: 10.1016/j.semradonc.2018.10.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 14.8] [Reference Citation Analysis]
285 Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med 2019;7:105. [PMID: 31019955 DOI: 10.21037/atm.2019.01.42] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 20.3] [Reference Citation Analysis]
286 Fan W, Tang W, Lau J, Shen Z, Xie J, Shi J, Chen X. Breaking the Depth Dependence by Nanotechnology-Enhanced X-Ray-Excited Deep Cancer Theranostics. Adv Mater 2019;31:e1806381. [PMID: 30698854 DOI: 10.1002/adma.201806381] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 18.5] [Reference Citation Analysis]
287 Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ. The Future of Radiobiology. J Natl Cancer Inst 2018;110:329-40. [PMID: 29126306 DOI: 10.1093/jnci/djx231] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
288 De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-johnson F. Radiotherapy toxicity. Nat Rev Dis Primers 2019;5. [DOI: 10.1038/s41572-019-0064-5] [Cited by in Crossref: 239] [Cited by in F6Publishing: 258] [Article Influence: 59.8] [Reference Citation Analysis]
289 Kato J, Hida T, Someya M, Sato S, Sawada M, Horimoto K, Fujioka M, Minowa T, Matsui Y, Tsuchiya T, Kitagawa M, Nakata K, Sakata K, Torigoe T, Uhara H. Efficacy of combined radiotherapy and anti‐programmed death 1 therapy in acral and mucosal melanoma. J Dermatol 2018;46:328-33. [DOI: 10.1111/1346-8138.14805] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
290 Zhou S, Zhao L, Liang Z, Liu S, Li Y, Liu S, Yang H, Liu M, Xi M. Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy. Cancers (Basel) 2019;11:E169. [PMID: 30717285 DOI: 10.3390/cancers11020169] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
291 Ozpiskin OM, Zhang L, Li JJ. Immune targets in the tumor microenvironment treated by radiotherapy. Theranostics 2019;9:1215-31. [PMID: 30867826 DOI: 10.7150/thno.32648] [Cited by in Crossref: 46] [Cited by in F6Publishing: 60] [Article Influence: 11.5] [Reference Citation Analysis]
292 Speranza MC, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, Kaufmann JK, Ahmed AK, Nowicki MO, Obi P, Bronisz A, Aguilar-Cordova E, Aguilar LK, Guzik BW, Breakefield X, Weissleder R, Freeman GJ, Reardon DA, Wen PY, Chiocca EA, Lawler SE. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol 2018;20:225-35. [PMID: 29016938 DOI: 10.1093/neuonc/nox139] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
293 Yang Y, Swierczak A, Ibahim M, Paiva P, Cann L, Stevenson AW, Crosbie JC, Anderson RL, Rogers PAW. Synchrotron microbeam radiotherapy evokes a different early tumor immunomodulatory response to conventional radiotherapy in EMT6.5 mammary tumors. Radiother Oncol 2019;133:93-9. [PMID: 30935588 DOI: 10.1016/j.radonc.2019.01.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
294 An M, Yu C, Xi J, Reyes J, Mao G, Wei WZ, Liu H. Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 2018;10:9311-9. [PMID: 29737353 DOI: 10.1039/c8nr01376d] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 14.5] [Reference Citation Analysis]
295 Fan TM, Selting KA. Exploring the Potential Utility of Pet Dogs With Cancer for Studying Radiation-Induced Immunogenic Cell Death Strategies. Front Oncol 2018;8:680. [PMID: 30697532 DOI: 10.3389/fonc.2018.00680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
296 Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? Front Immunol 2018;9:3107. [PMID: 30692993 DOI: 10.3389/fimmu.2018.03107] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
297 Mortezaee K, Goradel NH, Amini P, Shabeeb D, Musa AE, Najafi M, Farhood B. NADPH Oxidase as a Target for Modulation of Radiation Response; Implications to Carcinogenesis and Radiotherapy. CMP 2019;12:50-60. [DOI: 10.2174/1874467211666181010154709] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
298 Cai J, Wang H, Wang D, Li Y. Improving Cancer Vaccine Efficiency by Nanomedicine. Adv Biosyst 2019;3:e1800287. [PMID: 32627400 DOI: 10.1002/adbi.201800287] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
299 Chen Q, Chen M, Liu Z. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. Chem Soc Rev 2019;48:5506-26. [DOI: 10.1039/c9cs00271e] [Cited by in Crossref: 123] [Cited by in F6Publishing: 129] [Article Influence: 30.8] [Reference Citation Analysis]
300 Sang W, Zhang Z, Dai Y, Chen X. Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem Soc Rev 2019;48:3771-810. [DOI: 10.1039/c8cs00896e] [Cited by in Crossref: 195] [Cited by in F6Publishing: 208] [Article Influence: 48.8] [Reference Citation Analysis]
301 Dahl O, Brydøy M. The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. Acta Oncol 2019;58:1-8. [PMID: 30698061 DOI: 10.1080/0284186X.2018.1555375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
302 Dahl O, Dale JE, Brydøy M. Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment. Acta Oncol 2019;58:9-20. [PMID: 30632870 DOI: 10.1080/0284186X.2018.1554259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
303 Wu CT, Chen WC, Chen MF. The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation. Cancers (Basel) 2018;11:E20. [PMID: 30587810 DOI: 10.3390/cancers11010020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
304 Manca P, Raez LE, Salzberg M, Sanchez J, Hunis B, Rolfo C. The value of immunotherapy in head and neck cancer. Expert Opin Biol Ther 2019;19:35-43. [PMID: 30537444 DOI: 10.1080/14712598.2019.1556637] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
305 Dalgleish AG, Stern PL. The failure of radical treatments to cure cancer: can less deliver more? Ther Adv Vaccines Immunother 2018;6:69-76. [PMID: 30623172 DOI: 10.1177/2515135518815393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
306 Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC. Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Front Oncol 2018;8:609. [PMID: 30619749 DOI: 10.3389/fonc.2018.00609] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
307 Turgeon GA, Weickhardt A, Azad AA, Solomon B, Siva S. Radiotherapy and immunotherapy: a synergistic effect in cancer care. Med J Aust. 2019;210:47-53. [PMID: 30636308 DOI: 10.5694/mja2.12046] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
308 Stewart RD, Carlson DJ, Butkus MP, Hawkins R, Friedrich T, Scholz M. A comparison of mechanism-inspired models for particle relative biological effectiveness (RBE). Med Phys 2018;45:e925-52. [PMID: 30421808 DOI: 10.1002/mp.13207] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
309 Arcangeli S, Jereczek-Fossa BA, Alongi F, Aristei C, Becherini C, Belgioia L, Buglione M, Caravatta L, D'Angelillo RM, Filippi AR, Fiore M, Genovesi D, Greco C, Livi L, Magrini SM, Marvaso G, Mazzola R, Meattini I, Merlotti A, Palumbo I, Pergolizzi S, Ramella S, Ricardi U, Russi E, Trovò M, Sindoni A, Valentini V, Corvò R. Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. Crit Rev Oncol Hematol 2019;134:104-19. [PMID: 30658887 DOI: 10.1016/j.critrevonc.2018.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
310 Mahmood J, Shukla HD, Soman S, Samanta S, Singh P, Kamlapurkar S, Saeed A, Amin NP, Vujaskovic Z. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers (Basel). 2018;10. [PMID: 30486519 DOI: 10.3390/cancers10120469] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
311 Oliva S, Troia R, D'Agostino M, Boccadoro M, Gay F. Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. Front Immunol 2018;9:2749. [PMID: 30538704 DOI: 10.3389/fimmu.2018.02749] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 9.6] [Reference Citation Analysis]
312 Li Y, Li X, Zhou F, Doughty A, Hoover AR, Nordquist RE, Chen WR. Nanotechnology-based photoimmunological therapies for cancer. Cancer Lett 2019;442:429-38. [PMID: 30476523 DOI: 10.1016/j.canlet.2018.10.044] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
313 Jiang C, Zhu Y, Tang S, Zhang G, Lin Q, Xu Y, Shang J. High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. Oncol Lett 2019;17:1626-34. [PMID: 30675222 DOI: 10.3892/ol.2018.9747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
314 Cañas R, Linares I, Guedea F, Berenguer MÁ. Why should radiation oncology do translational research? [corrected]. Rep Pract Oncol Radiother 2019;24:60-4. [PMID: 30455615 DOI: 10.1016/j.rpor.2018.10.008] [Reference Citation Analysis]
315 Solanki AA, Bossi A, Efstathiou JA, Lock D, Mondini M, Ramapriyan R, Welsh J, Kang J. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. Eur Urol Oncol 2019;2:79-87. [PMID: 30929848 DOI: 10.1016/j.euo.2018.09.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
316 Bulner S, Prodeus A, Gariepy J, Hynynen K, Goertz DE. Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles. Ultrasound Med Biol 2019;45:500-12. [PMID: 30447880 DOI: 10.1016/j.ultrasmedbio.2018.10.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
317 Liu YL, Zamarin D. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. Curr Oncol Rep 2018;20:94. [PMID: 30421009 DOI: 10.1007/s11912-018-0740-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
318 Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. Mol Ther Oncolytics 2018;11:109-21. [PMID: 30569015 DOI: 10.1016/j.omto.2018.10.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
319 Gao H, Dong Z, Gong X, Dong J, Zhang Y, Wei W, Wang R, Jin S. Effects of various radiation doses on induced T-helper cell differentiation and related cytokine secretion. J Radiat Res 2018;59:395-403. [PMID: 29554285 DOI: 10.1093/jrr/rry011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
320 Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. Br J Cancer 2018;119:1171-81. [PMID: 30393372 DOI: 10.1038/s41416-018-0258-8] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 18.8] [Reference Citation Analysis]
321 Okonogi N, Suzuki Y, Sato H, Oike T, Yoshimoto Y, Mimura K, Noda SE, Okamoto M, Tamaki T, Morokoshi Y, Hasegawa S, Ohgaki H, Yokoo H, Nakano T. Combination Therapy of Intravenously Injected Microglia and Radiation Therapy Prolongs Survival in a Rat Model of Spontaneous Malignant Glioma. Int J Radiat Oncol Biol Phys 2018;102:601-8. [PMID: 29928947 DOI: 10.1016/j.ijrobp.2018.06.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
322 Sinclair G, Benmakhlouf H, Brigui M, Maeurer M, Dodoo E. The concept of rapid rescue radiosurgery in the acute management of critically located brain metastases: A retrospective short-term outcome analysis. Surg Neurol Int 2018;9:218. [PMID: 30505620 DOI: 10.4103/sni.sni_480_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
323 Tian JY, Guo FJ, Zheng GY, Ahmad A. Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities. Carcinogenesis 2018;39:307-17. [PMID: 29216344 DOI: 10.1093/carcin/bgx141] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
324 Poleszczuk J, Enderling H. The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity. Int J Mol Sci. 2018;19. [PMID: 30380596 DOI: 10.3390/ijms19113377] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
325 Galati D, Zanotta S. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Cytotherapy 2018;20:1309-23. [PMID: 30360963 DOI: 10.1016/j.jcyt.2018.09.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
326 Markovsky E, Budhu S, Samstein RM, Li H, Russell J, Zhang Z, Drill E, Bodden C, Chen Q, Powell SN, Merghoub T, Wolchok JD, Humm J, Deasy JO, Haimovitz-Friedman A. An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. Int J Radiat Oncol Biol Phys 2019;103:697-708. [PMID: 30342090 DOI: 10.1016/j.ijrobp.2018.10.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
327 Spałek M, Wyrwicz L. Hematological Toxicity of Hypofractionated Radiotherapy: A Review of the Available Evidence. Oncol Res Treat 2018;41:713-8. [DOI: 10.1159/000492342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
328 Matsuno Y, Hyodo M, Fujimori H, Shimizu A, Yoshioka KI. Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules. Cancers (Basel). 2018;10:pii: E364. [PMID: 30274183 DOI: 10.3390/cancers10100364] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
329 Helm A, Ebner DK, Tinganelli W, Simoniello P, Bisio A, Marchesano V, Durante M, Yamada S, Shimokawa T. Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments. Int J Part Ther 2018;5:84-93. [PMID: 31773022 DOI: 10.14338/IJPT-18-00024.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
330 Lee S, Son B, Park G, Kim H, Kang H, Jeon J, Youn H, Youn B. Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy. Int J Mol Sci 2018;19:E2795. [PMID: 30227629 DOI: 10.3390/ijms19092795] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
331 Voutsadakis IA. Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. World J Gastrointest Oncol 2018; 10(9): 221-227 [PMID: 30254717 DOI: 10.4251/wjgo.v10.i9.221] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
332 Kadlec B. The role of immunotherapy in the treatment of non-small cell lung cancer. Onkologie 2018;12:185-193. [DOI: 10.36290/xon.2018.034] [Reference Citation Analysis]
333 Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Front Immunol 2018;9:1977. [PMID: 30233579 DOI: 10.3389/fimmu.2018.01977] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 16.8] [Reference Citation Analysis]
334 Eckert F, Schaedle P, Zips D, Schmid-Horch B, Rammensee HG, Gani C, Gouttefangeas C. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology 2018;7:e1496881. [PMID: 30393582 DOI: 10.1080/2162402X.2018.1496881] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
335 Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Front Immunol 2018;9:1878. [PMID: 30158932 DOI: 10.3389/fimmu.2018.01878] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 15.8] [Reference Citation Analysis]
336 O'Beirn M, Benghiat H, Meade S, Heyes G, Sawlani V, Kong A, Hartley A, Sanghera P. The Expanding Role of Radiosurgery for Brain Metastases. Medicines (Basel) 2018;5:E90. [PMID: 30110927 DOI: 10.3390/medicines5030090] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
337 Chen HY, Xu L, Li LF, Liu XX, Gao JX, Bai YR. Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance. Sci Rep 2018;8:11934. [PMID: 30093664 DOI: 10.1038/s41598-018-30417-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 7.4] [Reference Citation Analysis]
338 Cen X, Liu S, Cheng K. The Role of Toll-Like Receptor in Inflammation and Tumor Immunity. Front Pharmacol 2018;9:878. [PMID: 30127747 DOI: 10.3389/fphar.2018.00878] [Cited by in Crossref: 85] [Cited by in F6Publishing: 92] [Article Influence: 17.0] [Reference Citation Analysis]
339 Wang B, An J, Zhang H, Zhang S, Zhang H, Wang L, Zhang H, Zhang Z. Personalized Cancer Immunotherapy via Transporting Endogenous Tumor Antigens to Lymph Nodes Mediated by Nano Fe 3 O 4. Small 2018;14:1801372. [DOI: 10.1002/smll.201801372] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
340 Zhuang Y, Li S, Wang H, Pi J, Xing Y, Li G. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models. J Cancer Res Clin Oncol 2018;144:1909-20. [PMID: 30074066 DOI: 10.1007/s00432-018-2723-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
341 Yu C, Liu H. New Strategies to Improve Therapeutic Vaccines. Immunoregulatory Aspects of Immunotherapy 2018. [DOI: 10.5772/intechopen.74900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
342 Silva-Figueroa A, Villalobos P, Williams MD, Bassett RL Jr, Clarke CN, Lee JE, Busaidy NL, Perrier ND. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Surgery 2018;164:960-4. [PMID: 30033186 DOI: 10.1016/j.surg.2018.06.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
343 Buttigliero C, Allis S, Tucci M, Zichi C, Leone G, Di Stefano RF, Ruo Redda MG, Ricardi U, Scagliotti GV, Di Maio M, Filippi AR. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treat Rev 2018;69:215-23. [PMID: 30096699 DOI: 10.1016/j.ctrv.2018.07.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
344 Bravatà V, Minafra L, Cammarata FP, Pisciotta P, Lamia D, Marchese V, Petringa G, Manti L, Cirrone GA, Gilardi MC, Cuttone G, Forte GI, Russo G. Gene expression profiling of breast cancer cell lines treated with proton and electron radiations. Br J Radiol 2018;91:20170934. [PMID: 29888960 DOI: 10.1259/bjr.20170934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
345 Seo JW, Tavaré R, Mahakian LM, Silvestrini MT, Tam S, Ingham ES, Salazar FB, Borowsky AD, Wu AM, Ferrara KW. CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 2018;24:4976-87. [PMID: 29967252 DOI: 10.1158/1078-0432.CCR-18-0261] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 11.8] [Reference Citation Analysis]
346 Genard G, Wera AC, Huart C, Le Calve B, Penninckx S, Fattaccioli A, Tabarrant T, Demazy C, Ninane N, Heuskin AC, Lucas S, Michiels C. Proton irradiation orchestrates macrophage reprogramming through NFκB signaling. Cell Death Dis 2018;9:728. [PMID: 29950610 DOI: 10.1038/s41419-018-0757-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
347 Jiang L, Ding Y, Xue X, Zhou S, Li C, Zhang X, Jiang X. Entrapping multifunctional dendritic nanoparticles into a hydrogel for local therapeutic delivery and synergetic immunochemotherapy. Nano Res 2018;11:6062-73. [DOI: 10.1007/s12274-018-2123-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
348 Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci Rep 2018;8:9474. [PMID: 29930290 DOI: 10.1038/s41598-018-27718-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
349 Blasco AS, Cortes CV, Arcuch VS, Letelier RB, Caprio SB. Radiation Therapy for Non-Small Cell Lung Cancer in the Twenty-First Century. Cancer Management and Therapy 2018. [DOI: 10.5772/intechopen.76513] [Reference Citation Analysis]
350 Abravan A, Eide HA, Løndalen AM, Helland Å, Malinen E. Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer. Mol Imaging Biol 2019;21:391-8. [DOI: 10.1007/s11307-018-1226-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
351 Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo N, La Riviere P, Weichselbaum RR, Lin W. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 2018;9:2351. [PMID: 29907739 DOI: 10.1038/s41467-018-04703-w] [Cited by in Crossref: 176] [Cited by in F6Publishing: 187] [Article Influence: 35.2] [Reference Citation Analysis]
352 Chavez M, Silvestrini MT, Ingham ES, Fite BZ, Mahakian LM, Tam SM, Ilovitsh A, Monjazeb AM, Murphy WJ, Hubbard NE, Davis RR, Tepper CG, Borowsky AD, Ferrara KW. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. Theranostics 2018;8:3611-28. [PMID: 30026870 DOI: 10.7150/thno.25613] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
353 Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 2018;6:46. [PMID: 29866197 DOI: 10.1186/s40425-018-0361-7] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 16.6] [Reference Citation Analysis]
354 Rouanne M, Roumiguié M, Houédé N, Masson-Lecomte A, Colin P, Pignot G, Larré S, Xylinas E, Rouprêt M, Neuzillet Y. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol 2018;36:1727-40. [PMID: 29855698 DOI: 10.1007/s00345-018-2332-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
355 Lee K, Kim M, Seo Y, Lee H. Development of mRNA vaccines and their prophylactic and therapeutic applications. Nano Res 2018;11:5173-92. [DOI: 10.1007/s12274-018-2095-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
356 Ehlerding EB, Ferreira CA, Aluicio-Sarduy E, Jiang D, Lee HJ, Theuer CP, Engle JW, Cai W. 86/90Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model. Mol Pharm 2018;15:2606-13. [PMID: 29787283 DOI: 10.1021/acs.molpharmaceut.8b00133] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
357 Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249-279. [PMID: 29027221 DOI: 10.1111/imr.12573] [Cited by in Crossref: 105] [Cited by in F6Publishing: 115] [Article Influence: 21.0] [Reference Citation Analysis]
358 Spirou SV, Costa Lima SA, Bouziotis P, Vranješ-Djurić S, Efthimiadou EΚ, Laurenzana A, Barbosa AI, Garcia-Alonso I, Jones C, Jankovic D, Gobbo OL. Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy. Nanomaterials (Basel) 2018;8:E306. [PMID: 29734795 DOI: 10.3390/nano8050306] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
359 Tallet AV, Dhermain F, Le Rhun E, Noël G, Kirova YM. Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. Ann Oncol 2017;28:2962-76. [PMID: 29045524 DOI: 10.1093/annonc/mdx408] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
360 Gabani P, Robinson CG, Ansstas G, Johanns TM, Huang J. Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy. Radiotherapy and Oncology 2018;127:310-7. [DOI: 10.1016/j.radonc.2018.02.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
361 Chu D, Dong X, Shi X, Zhang C, Wang Z. Neutrophil-Based Drug Delivery Systems. Adv Mater 2018;30:e1706245. [PMID: 29577477 DOI: 10.1002/adma.201706245] [Cited by in Crossref: 133] [Cited by in F6Publishing: 142] [Article Influence: 26.6] [Reference Citation Analysis]
362 Bhalla N, Brooker R, Brada M. Combining immunotherapy and radiotherapy in lung cancer. J Thorac Dis 2018;10:S1447-60. [PMID: 29951296 DOI: 10.21037/jtd.2018.05.107] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
363 Filippi AR, Di Muzio J, Badellino S, Mantovani C, Ricardi U. Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance? J Thorac Dis 2018;10:S1461-7. [PMID: 29951297 DOI: 10.21037/jtd.2017.12.53] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
364 Peng L, Wu YL. Immunotherapy in the Asiatic population: any differences from Caucasian population? J Thorac Dis 2018;10:S1482-93. [PMID: 29951300 DOI: 10.21037/jtd.2018.05.106] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
365 Gutting T, Burgermeister E, Härtel N, Ebert MP. Checkpoints and beyond - Immunotherapy in colorectal cancer. Semin Cancer Biol 2019;55:78-89. [PMID: 29716829 DOI: 10.1016/j.semcancer.2018.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
366 Franzese O, Torino F, Fuggetta MP, Aquino A, Roselli M, Bonmassar E, Giuliani A, D'Atri S. Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. Oncotarget 2017;8:41641-69. [PMID: 28404974 DOI: 10.18632/oncotarget.16335] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
367 McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Fragoso RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, Monjazeb AM. Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys 2018;101:1259-70. [PMID: 29891204 DOI: 10.1016/j.ijrobp.2018.04.038] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
368 Bravatà V, Cava C, Minafra L, Cammarata FP, Russo G, Gilardi MC, Castiglioni I, Forte GI. Radiation-Induced Gene Expression Changes in High and Low Grade Breast Cancer Cell Types. Int J Mol Sci 2018;19:E1084. [PMID: 29617354 DOI: 10.3390/ijms19041084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
369 Mehta S, Illidge T, Choudhury A. Immunotherapy with radiotherapy in urological malignancies. Curr Opin Urol 2016;26:514-22. [PMID: 27552139 DOI: 10.1097/MOU.0000000000000335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
370 Liao Z, Simone CB 2nd. Particle therapy in non-small cell lung cancer. Transl Lung Cancer Res 2018;7:141-52. [PMID: 29876313 DOI: 10.21037/tlcr.2018.04.11] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
371 Lee HJ, Zeng J, Rengan R. Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. Transl Lung Cancer Res. 2018;7:180-188. [PMID: 29876317 DOI: 10.21037/tlcr.2018.03.28] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
372 Thangamathesvaran L, Shah R, Verma R, Mahmoud O. Immune checkpoint inhibitors and radiotherapy-concept and review of current literature. Ann Transl Med 2018;6:155. [PMID: 29862244 DOI: 10.21037/atm.2018.03.09] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
373 Liao Z, Gandhi SJ, Lin SH, Bradley J. Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors? Seminars in Radiation Oncology 2018;28:114-24. [DOI: 10.1016/j.semradonc.2017.11.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
374 Santoni G, Amantini C, Morelli MB, Tomassoni D, Santoni M, Marinelli O, Nabissi M, Cardinali C, Paolucci V, Torniai M, Rinaldi S, Morgese F, Bernardini G, Berardi R. High CTLA-4 expression correlates with poor prognosis in thymoma patients. Oncotarget 2018;9:16665-77. [PMID: 29682176 DOI: 10.18632/oncotarget.24645] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
375 Lu K, He C, Guo N, Chan C, Ni K, Lan G, Tang H, Pelizzari C, Fu Y, Spiotto MT, Weichselbaum RR, Lin W. Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng 2018;2:600-10. [DOI: 10.1038/s41551-018-0203-4] [Cited by in Crossref: 315] [Cited by in F6Publishing: 324] [Article Influence: 63.0] [Reference Citation Analysis]
376 Zuo C, Sheng X, Ma M, Xia M, Ouyang L. ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Oncotarget 2016;7:74393-409. [PMID: 27626310 DOI: 10.18632/oncotarget.11911] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
377 Tran TH, Tran TTP, Nguyen HT, Phung CD, Jeong JH, Stenzel MH, Jin SG, Yong CS, Truong DH, Kim JO. Nanoparticles for dendritic cell-based immunotherapy. Int J Pharm 2018;542:253-65. [PMID: 29555438 DOI: 10.1016/j.ijpharm.2018.03.029] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
378 Johnson CB, Win SY. Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials. Oncoimmunology 2018;7:e1408744. [PMID: 29632719 DOI: 10.1080/2162402X.2017.1408744] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
379 Yuan C, Wang Q. Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients. Clin Transl Oncol 2018;20:1219-25. [PMID: 29536332 DOI: 10.1007/s12094-018-1851-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
380 Spetz J, Rudqvist N, Langen B, Parris TZ, Dalmo J, Schüler E, Wängberg B, Nilsson O, Helou K, Forssell-Aronsson E. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu[Lu]-octreotate therapy. Nucl Med Biol 2018;60:11-8. [PMID: 29502008 DOI: 10.1016/j.nucmedbio.2018.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
381 McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR Jr, Gough MJ, Raber J. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget 2017;8:9155-73. [PMID: 27893434 DOI: 10.18632/oncotarget.13551] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
382 Connolly KA, Belt BA, Figueroa NM, Murthy A, Patel A, Kim M, Lord EM, Linehan DC, Gerber SA. Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes. Oncotarget 2016;7:86522-35. [PMID: 27852031 DOI: 10.18632/oncotarget.13287] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
383 De Felice F, Polimeni A, Valentini V, Brugnoletti O, Cassoni A, Greco A, de Vincentiis M, Tombolini V. Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review. Neoplasia 2018;20:227-32. [PMID: 29448084 DOI: 10.1016/j.neo.2018.01.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
384 Khandekar MJ, Jain R. Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 2018;7:S16-20. [PMID: 30175050 DOI: 10.21037/tcr.2017.12.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
385 Ngoi NYL, Heong V, Lee XW, Huang YQ, Thian YL, Choo BA, Lim D, Lim YW, Lim SE, Ilancheran A, Soong R, Tan DSP. Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecol Oncol Rep 2018;24:1-5. [PMID: 29892689 DOI: 10.1016/j.gore.2018.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
386 Sahu RP, Harrison KA, Weyerbacher J, Murphy RC, Konger RL, Garrett JE, Chin-Sinex HJ, Johnston ME 2nd, Dynlacht JR, Mendonca M, McMullen K, Li G, Spandau DF, Travers JB. Radiation therapy generates platelet-activating factor agonists. Oncotarget 2016;7:20788-800. [PMID: 26959112 DOI: 10.18632/oncotarget.7878] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
387 Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol 2018;10:1758834017742575. [PMID: 29383033 DOI: 10.1177/1758834017742575] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 23.0] [Reference Citation Analysis]
388 Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016;2:286-294. [PMID: 27774519 DOI: 10.1016/j.trecan.2016.05.002] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 39.6] [Reference Citation Analysis]
389 Basler L, Kowalczyk A, Heidenreich R, Fotin-Mleczek M, Tsitsekidis S, Zips D, Eckert F, Huber SM. Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. Cancer Immunol Immunother 2018;67:653-62. [PMID: 29335856 DOI: 10.1007/s00262-018-2117-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
390 Rekers NH, Olivo Pimentel V, Yaromina A, Lieuwes NG, Biemans R, Zegers CML, Germeraad WTV, Van Limbergen EJ, Neri D, Dubois LJ, Lambin P. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Oncoimmunology 2018;7:e1414119. [PMID: 29632732 DOI: 10.1080/2162402X.2017.1414119] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
391 Pires BRB, Silva RCMC, Ferreira GM, Abdelhay E. NF-kappaB: Two Sides of the Same Coin. Genes (Basel) 2018;9:E24. [PMID: 29315242 DOI: 10.3390/genes9010024] [Cited by in Crossref: 128] [Cited by in F6Publishing: 142] [Article Influence: 25.6] [Reference Citation Analysis]
392 Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu YX, Weichselbaum RR. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget 2016;7:43039-51. [PMID: 27343548 DOI: 10.18632/oncotarget.9915] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
393 Tchelebi L, Zaorsky N, Mackley H. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines 2018;6:E7. [PMID: 29301352 DOI: 10.3390/biomedicines6010007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
394 Martínez-Torres AC, Reyes-Ruiz A, Benítez-Londoño M, Franco-Molina MA, Rodríguez-Padilla C. IMMUNEPOTENT CRP induces cell cycle arrest and caspase-independent regulated cell death in HeLa cells through reactive oxygen species production. BMC Cancer 2018;18:13. [PMID: 29298674 DOI: 10.1186/s12885-017-3954-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
395 Stephen B, Hajjar J. Overview of Basic Immunology and Translational Relevance for Clinical Investigators. Advances in Experimental Medicine and Biology 2018. [DOI: 10.1007/978-3-030-02505-2_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
396 Abe K. Resistance to Y-90 Ibritumomab Tiuxetan Therapy. Resistance to Targeted Anti-Cancer Therapeutics 2018. [DOI: 10.1007/978-3-319-78238-6_3] [Reference Citation Analysis]
397 Gorin J, Ménager J, Guilloux Y, Chatal J, Gaschet J, Chérel M. Combining RAIT and Immune-Based Therapies to Overcome Resistance in Cancer? Resistance to Targeted Anti-Cancer Therapeutics 2018. [DOI: 10.1007/978-3-319-78238-6_9] [Reference Citation Analysis]
398 Qiao M, Jiang T, Ren S, Zhou C. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand? Clinical Lung Cancer 2018;19:1-11. [DOI: 10.1016/j.cllc.2017.06.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
399 Vu P, Bazhenova L. Thoracic Immunotherapy. Early Phase Cancer Immunotherapy 2018. [DOI: 10.1007/978-3-319-63757-0_10] [Reference Citation Analysis]
400 Demaria S, Bornstein S, Formenti SC. Synergy Between Radiotherapy and Immunotherapy. Oncoimmunology 2018. [DOI: 10.1007/978-3-319-62431-0_30] [Reference Citation Analysis]
401 Moy J, Ferris RL. Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). Molecular Determinants of Head and Neck Cancer 2018. [DOI: 10.1007/978-3-319-78762-6_14] [Reference Citation Analysis]
402 Ribeiro AM, Amaral C, Veiga F, Figueiras A. Polymeric micelles as a versatile tool in oral chemotherapy. Design and Development of New Nanocarriers 2018. [DOI: 10.1016/b978-0-12-813627-0.00008-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
403 Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH. Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget 2016;7:34907-17. [PMID: 27145458 DOI: 10.18632/oncotarget.8995] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
404 Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol 2018;18:183-94. [PMID: 29279613 DOI: 10.1038/nri.2017.140] [Cited by in Crossref: 120] [Cited by in F6Publishing: 124] [Article Influence: 20.0] [Reference Citation Analysis]
405 Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Semin Cancer Biol 2018;52:125-34. [PMID: 29258856 DOI: 10.1016/j.semcancer.2017.12.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
406 Rao M, Zhenjiang L, Meng Q, Sinclair G, Dodoo E, Maeurer M. Mutant Epitopes in Cancer. In: Zitvogel L, Kroemer G, editors. Oncoimmunology. Cham: Springer International Publishing; 2018. pp. 41-67. [DOI: 10.1007/978-3-319-62431-0_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
407 Noe C, Baumann V. Personalized Medicine. Methods and Principles in Medicinal Chemistry 2017. [DOI: 10.1002/9783527674381.ch5] [Reference Citation Analysis]
408 Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017;8:1079-99. [PMID: 29299370 DOI: 10.21037/jgo.2017.09.10] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
409 De Ruysscher D, Jin J, Lautenschlaeger T, She JX, Liao Z, Kong FS. Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy. Transl Lung Cancer Res 2017;6:661-9. [PMID: 29218269 DOI: 10.21037/tlcr.2017.09.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
410 Chang MC, Chen YL, Lin HW, Chiang YC, Chang CF, Hsieh SF, Chen CA, Sun WZ, Cheng WF. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment. Mol Ther 2018;26:404-19. [PMID: 29248428 DOI: 10.1016/j.ymthe.2017.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
411 Blyth BJ, Cole AJ, MacManus MP, Martin OA. Radiation therapy-induced metastasis: radiobiology and clinical implications. Clin Exp Metastasis 2018;35:223-36. [PMID: 29159430 DOI: 10.1007/s10585-017-9867-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
412 Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med 2017;15:236. [PMID: 29145885 DOI: 10.1186/s12967-017-1341-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
413 Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med 2018;283:110-20. [DOI: 10.1111/joim.12708] [Cited by in Crossref: 112] [Cited by in F6Publishing: 119] [Article Influence: 18.7] [Reference Citation Analysis]
414 Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, Fae' DA, Berretta M, Militello L, Del Conte A, Spazzapan S, Dolcetti R, Trovo' M. Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. Front Immunol 2017;8:1476. [PMID: 29163540 DOI: 10.3389/fimmu.2017.01476] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
415 Veisi Z, Ravanshadi S, Khadem H, Veisi Z, Ravanshadi S, Khadem H. Investigation of the Effect of Adding Stem Cells-as an Therapeutic Suggestion-on the Immune System's Response to the Cancerous Cells: A Mathematical Approach. 2017 24th National and 2nd International Iranian Conference on Biomedical Engineering (ICBME) 2017. [DOI: 10.1109/icbme.2017.8430249] [Reference Citation Analysis]
416 Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol 2017;18:e653-706. [PMID: 29208398 DOI: 10.1016/S1470-2045(17)30698-8] [Cited by in Crossref: 112] [Cited by in F6Publishing: 120] [Article Influence: 18.7] [Reference Citation Analysis]
417 Son CH, Fleming GF, Moroney JW. Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. Cancer Manag Res 2017;9:553-63. [PMID: 29184441 DOI: 10.2147/CMAR.S116683] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
418 Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola FM, Bedognetti D, Hendrickx W. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. Int J Mol Sci 2017;18:E2229. [PMID: 29064420 DOI: 10.3390/ijms18102229] [Cited by in Crossref: 77] [Cited by in F6Publishing: 83] [Article Influence: 12.8] [Reference Citation Analysis]
419 Cho O, Chun M, Oh YT, Noh OK, Chang SJ, Ryu HS, Lee EJ. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. Tumour Biol 2017;39:1010428317733144. [PMID: 29022484 DOI: 10.1177/1010428317734303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
420 Oguejiofor K, Galletta-Williams H, Dovedi SJ, Roberts DL, Stern PL, West CM. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget 2017;8:14416-27. [PMID: 28122336 DOI: 10.18632/oncotarget.14796] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 9.8] [Reference Citation Analysis]
421 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 227] [Cited by in F6Publishing: 248] [Article Influence: 37.8] [Reference Citation Analysis]
422 Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749-762. [PMID: 28975929 DOI: 10.1038/nrclinonc.2017.141] [Cited by in Crossref: 1825] [Cited by in F6Publishing: 1968] [Article Influence: 304.2] [Reference Citation Analysis]
423 Shi F, Wang X, Teng F, Kong L, Yu J. Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy. Cancer Biol Ther 2017;18:137-41. [PMID: 28267380 DOI: 10.1080/15384047.2016.1276133] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
424 Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, Muschel RJ, Fokas E. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med 2017;9:167-80. [PMID: 27932443 DOI: 10.15252/emmm.201606674] [Cited by in Crossref: 110] [Cited by in F6Publishing: 121] [Article Influence: 18.3] [Reference Citation Analysis]
425 Ohri N. Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? Front Oncol 2017;7:205. [PMID: 28983464 DOI: 10.3389/fonc.2017.00205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
426 Pianko MJ, Moskowitz AJ, Lesokhin AM. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clin Cancer Res 2018;24:1002-10. [PMID: 28899972 DOI: 10.1158/1078-0432.CCR-17-0539] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
427 Galati D, Zanotta S. Hematologic neoplasms: Dendritic cells vaccines in motion. Clin Immunol 2017;183:181-90. [PMID: 28870867 DOI: 10.1016/j.clim.2017.08.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
428 Peyraud F, Cousin S, Italiano A. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep 2017;19:70. [PMID: 28875266 DOI: 10.1007/s11912-017-0634-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
429 Tan AC, Heimberger AB, Khasraw M. Immune Checkpoint Inhibitors in Gliomas. Curr Oncol Rep 2017;19:23. [PMID: 28303490 DOI: 10.1007/s11912-017-0586-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
430 Tsai MS, Chen WC, Lai CH, Chen YY, Chen MF. Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer. Oral Oncol 2017;73:88-96. [PMID: 28939082 DOI: 10.1016/j.oraloncology.2017.08.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
431 El Chediak A, Shamseddine A, Bodgi L, Obeid JP, Geara F, Zeidan YH. Optimizing tumor immune response through combination of radiation and immunotherapy. Med Oncol 2017;34:165. [PMID: 28828581 DOI: 10.1007/s12032-017-1025-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
432 Fields EC, McGuire WP, Lin L, Temkin SM. Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. Front Oncol 2017;7:177. [PMID: 28871275 DOI: 10.3389/fonc.2017.00177] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
433 Trivillin VA, Pozzi ECC, Colombo LL, Thorp SI, Garabalino MA, Monti Hughes A, González SJ, Farías RO, Curotto P, Santa Cruz GA, Carando DG, Schwint AE. Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer. Radiat Environ Biophys 2017;56:365-75. [PMID: 28791476 DOI: 10.1007/s00411-017-0704-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
434 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
435 de la Torre AN, Contractor S, Castaneda I, Cathcart CS, Razdan D, Klyde D, Kisza P, Gonzales SF, Salazar AM. A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. J Hepatocell Carcinoma 2017;4:111-21. [PMID: 28848723 DOI: 10.2147/JHC.S136652] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
436 De Ruysscher D, Granton PV, Lieuwes NG, van Hoof S, Wollin L, Weynand B, Dingemans AM, Verhaegen F, Dubois L. Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator. Radiother Oncol 2017;124:482-7. [PMID: 28774597 DOI: 10.1016/j.radonc.2017.07.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
437 Vanpouille-Box C, Formenti SC, Demaria S. Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clin Cancer Res 2018;24:259-65. [PMID: 28751442 DOI: 10.1158/1078-0432.CCR-16-0037] [Cited by in Crossref: 106] [Cited by in F6Publishing: 115] [Article Influence: 17.7] [Reference Citation Analysis]
438 Vandenabeele P, Vandecasteele K, Bachert C, Krysko O, Krysko DV. Immunogenic Apoptotic Cell Death and Anticancer Immunity. Adv Exp Med Biol 2016;930:133-49. [PMID: 27558820 DOI: 10.1007/978-3-319-39406-0_6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 9.8] [Reference Citation Analysis]
439 Alberti C. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. G Chir 2017;37:225-35. [PMID: 28098061 DOI: 10.11138/gchir/2016.37.5.225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
440 Yasuda T, Kamahori M, Nagata K, Watanabe-Asaka T, Suzuki M, Funayama T, Mitani H, Oda S. Abscopal Activation of Microglia in Embryonic Fish Brain Following Targeted Irradiation with Heavy-Ion Microbeam. Int J Mol Sci 2017;18:E1428. [PMID: 28677658 DOI: 10.3390/ijms18071428] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
441 Verma N, Tiku AB. Significance and nature of bystander responses induced by various agents. Mutation Research/Reviews in Mutation Research 2017;773:104-21. [DOI: 10.1016/j.mrrev.2017.05.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
442 Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev 2017;58:22-33. [PMID: 28622628 DOI: 10.1016/j.ctrv.2017.05.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
443 Xie G, Gu D, Zhang L, Chen S, Wu D. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. Cancer Biol Ther 2017;18:547-51. [PMID: 28665741 DOI: 10.1080/15384047.2017.1345389] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
444 Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol 2017;12:877-82. [PMID: 28650437 DOI: 10.1038/nnano.2017.113] [Cited by in Crossref: 382] [Cited by in F6Publishing: 405] [Article Influence: 63.7] [Reference Citation Analysis]
445 Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB. A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clin Cancer Res 2017;23:5055-65. [PMID: 28630212 DOI: 10.1158/1078-0432.CCR-16-2946] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
446 Kouhsari E, Ghadimi-daresajini A, Abdollahi H, Amirmozafari N, Mahdavi SR, Abbasian S, Mousavi SH, Yaseri HF, Moghaderi M. The potential roles of bacteria to improve radiation treatment outcome. Clin Transl Oncol 2018;20:127-39. [DOI: 10.1007/s12094-017-1701-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
447 Horne TK, Cronjé MJ. Novel carbohydrate-substituted metallo-porphyrazine comparison for cancer tissue-type specificity during PDT. J Photochem Photobiol B 2017;173:412-22. [PMID: 28662468 DOI: 10.1016/j.jphotobiol.2017.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
448 Ebner DK, Kamada T, Yamada S. Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports. Adv Radiat Oncol. 2017;2:333-338. [PMID: 29114600 DOI: 10.1016/j.adro.2017.06.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
449 Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P. Immunotherapy and radiation in glioblastoma. J Neurooncol 2017;134:531-9. [DOI: 10.1007/s11060-017-2413-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
450 Bakker E, Guazzelli A, Krstic-demonacos M, Lisanti M, Sotgia F, Mutti L. Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. Expert Opinion on Orphan Drugs 2017;5:455-65. [DOI: 10.1080/21678707.2017.1325358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
451 Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer 2017;116:1558-63. [PMID: 28524161 DOI: 10.1038/bjc.2017.142] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 11.5] [Reference Citation Analysis]
452 Baues C, Trommer-Nestler M, Jablonska K, Bröckelmann PJ, Schlaak M, von Bergwelt-Baildon M, Engert A, Semrau R, Marnitz S, Theurich S. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. Immunotherapy 2017;9:423-33. [PMID: 28357914 DOI: 10.2217/imt-2017-0002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
453 Elgström E, Ohlsson TG, Eriksson SE. Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model. Tumour Biol 2017;39:1010428317697550. [PMID: 28381167 DOI: 10.1177/1010428317697550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
454 Liu LT, Chen QY, Tang LQ, Guo SS, Guo L, Mo HY, Chen MY, Zhao C, Guo X, Qian CN, Zeng MS, Bei JX, Tan J, Chen S, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ. The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. Cancer Res Treat 2018;50:19-29. [PMID: 28392551 DOI: 10.4143/crt.2016.595] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
455 Sun Y, Zheng Z, Zhang H, Yu Y, Ma J, Tang K, Xu P, Ji T, Liang X, Chen D, Jin X, Zhang T, Long Z, Liu Y, Huang B. Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathway. Oncoimmunology 2017;6:e1309487. [PMID: 28680743 DOI: 10.1080/2162402X.2017.1309487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
456 Janiak MK, Wincenciak M, Cheda A, Nowosielska EM, Calabrese EJ. Cancer immunotherapy: how low-level ionizing radiation can play a key role. Cancer Immunol Immunother 2017;66:819-32. [PMID: 28361232 DOI: 10.1007/s00262-017-1993-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
457 Silvestrini MT, Ingham ES, Mahakian LM, Kheirolomoom A, Liu Y, Fite BZ, Tam SM, Tucci ST, Watson KD, Wong AW, Monjazeb AM, Hubbard NE, Murphy WJ, Borowsky AD, Ferrara KW. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. JCI Insight 2017;2:e90521. [PMID: 28352658 DOI: 10.1172/jci.insight.90521] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 9.5] [Reference Citation Analysis]
458 Stankevicius V, Kuodyte K, Schveigert D, Bulotiene D, Paulauskas T, Daniunaite K, Suziedelis K. Gene and miRNA expression profiles of mouse Lewis lung carcinoma LLC1 cells following single or fractionated dose irradiation. Oncol Lett 2017;13:4190-200. [PMID: 28599420 DOI: 10.3892/ol.2017.5877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
459 Liu H, Li B, Jia X, Ma Y, Gu Y, Zhang P, Wei Q, Cai J, Cui J, Gao F, Yang Y. Radiation-induced decrease of CD8+ dendritic cells contributes to Th1/Th2 shift. Int Immunopharmacol 2017;46:178-85. [PMID: 28314222 DOI: 10.1016/j.intimp.2017.03.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
460 Guo G, Yu M, Xiao W, Celis E, Cui Y. Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. Cancer Res 2017;77:2292-305. [PMID: 28280037 DOI: 10.1158/0008-5472.CAN-16-2832] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 13.0] [Reference Citation Analysis]
461 Rasmussen JC, Tan IC, Naqvi S, Aldrich MB, Maus EA, Blanco AI, Karni RJ, Sevick-Muraca EM. Longitudinal monitoring of the head and neck lymphatics in response to surgery and radiation. Head Neck 2017;39:1177-88. [PMID: 28263428 DOI: 10.1002/hed.24750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
462 Maia MC, Hansen AR. A comprehensive review of immunotherapies in prostate cancer. Crit Rev Oncol Hematol 2017;113:292-303. [PMID: 28427519 DOI: 10.1016/j.critrevonc.2017.02.026] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
463 Schlom J, Gulley JL, Hodge JW. Vaccines and Immunostimulants. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm066] [Reference Citation Analysis]
464 Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5:16. [PMID: 28239469 DOI: 10.1186/s40425-017-0218-5] [Cited by in Crossref: 239] [Cited by in F6Publishing: 251] [Article Influence: 39.8] [Reference Citation Analysis]
465 Santarpia M, Karachaliou N, Rosell R. Beyond platinum treatment for NSCLC: what does the future hold? Expert Rev Anticancer Ther 2017;17:293-5. [PMID: 28129003 DOI: 10.1080/14737140.2017.1288103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
466 Ebner DK, Tinganelli W, Helm A, Bisio A, Yamada S, Kamada T, Shimokawa T, Durante M. The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. Front Immunol 2017;8:99. [PMID: 28220126 DOI: 10.3389/fimmu.2017.00099] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
467 Li QX, Feuer G, Ouyang X, An X. Experimental animal modeling for immuno-oncology. Pharmacol Ther 2017;173:34-46. [PMID: 28167217 DOI: 10.1016/j.pharmthera.2017.02.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
468 Eckert F, Gaipl US, Niedermann G, Hettich M, Schilbach K, Huber SM, Zips D. Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation. Clin Transl Radiat Oncol 2017;2:29-35. [PMID: 29657997 DOI: 10.1016/j.ctro.2016.12.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
469 Skrepnik T, Sundararajan S, Cui H, Stea B. Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology 2017;6:e1283461. [PMID: 28405509 DOI: 10.1080/2162402X.2017.1283461] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
470 Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer 2017;5:4. [PMID: 28116088 DOI: 10.1186/s40425-016-0204-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
471 Weichselbaum RR, Liang H, Deng L, Fu Y. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 2017;14:365-79. [DOI: 10.1038/nrclinonc.2016.211] [Cited by in Crossref: 540] [Cited by in F6Publishing: 564] [Article Influence: 90.0] [Reference Citation Analysis]
472 Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RT, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EE, Even AJ, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RT, Zegers CM, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev 2017;109:131-53. [PMID: 26774327 DOI: 10.1016/j.addr.2016.01.006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 86] [Article Influence: 12.2] [Reference Citation Analysis]
473 Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, Ishkanian A. Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. Cancer Res 2017;77:1310-21. [PMID: 28082399 DOI: 10.1158/0008-5472.CAN-16-2105] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
474 Samstein RM, Budhu S, Mergoub T, Barker CA. Combining Radiotherapy and Immunotherapy: Emerging Preclinical Observations of Lymphocyte Costimulatory and Inhibitory Receptor Modulation. Cancer Drug Discovery and Development 2017. [DOI: 10.1007/978-3-319-40854-5_7] [Reference Citation Analysis]
475 Zhu Y, Paniccia A, Edil BH, Schulick RD. Development of Cancer Vaccine and Targeted Immune Checkpoint Therapies. Innovation of Diagnosis and Treatment for Pancreatic Cancer 2017. [DOI: 10.1007/978-981-10-2486-3_16] [Reference Citation Analysis]
476 Cho JH, Kim AR, Kim SH, Lee SJ, Chung H, Yoon MY. Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. Acta Biomater 2017;47:182-92. [PMID: 27721007 DOI: 10.1016/j.actbio.2016.10.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
477 Milam RW, Batson SA, Breazzano MP, Ayala-peacock DN, Daniels AB. Modern and Novel Radiotherapy Approaches for the Treatment of Uveal Melanoma. International Ophthalmology Clinics 2017;57:11-27. [DOI: 10.1097/iio.0000000000000153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
478 Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res. 2016;22:1845-1855. [PMID: 27084738 DOI: 10.1158/1078-0432.ccr-16-0049] [Cited by in Crossref: 182] [Cited by in F6Publishing: 193] [Article Influence: 26.0] [Reference Citation Analysis]
479 Koo T, Kim IA. Radiotherapy and immune checkpoint blockades: a snapshot in 2016. Radiat Oncol J 2016;34:250-9. [PMID: 28030901 DOI: 10.3857/roj.2016.02033] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
480 Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater 2017;16:489-96. [PMID: 28024156 DOI: 10.1038/nmat4822] [Cited by in Crossref: 599] [Cited by in F6Publishing: 621] [Article Influence: 85.6] [Reference Citation Analysis]
481 van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH. Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients. Oncoimmunology 2017;6:e1267095. [PMID: 28344877 DOI: 10.1080/2162402X.2016.1267095] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 10.0] [Reference Citation Analysis]
482 Heong V, Ngoi N, Tan DS. Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol 2017;28:e20. [PMID: 28028993 DOI: 10.3802/jgo.2017.28.e20] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
483 Hao Y, Yasmin-Karim S, Moreau M, Sinha N, Sajo E, Ngwa W. Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study. Phys Med Biol 2016;61:N697-707. [PMID: 27910826 DOI: 10.1088/1361-6560/61/24/N697] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
484 Bernier J. Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing. Critical Reviews in Oncology/Hematology 2016;108:97-108. [DOI: 10.1016/j.critrevonc.2016.11.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
485 Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2017;123:1259-71. [PMID: 27906454 DOI: 10.1002/cncr.30449] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
486 Ricardi U, Badellino S, Filippi AR. What do radiation oncologists require for future advancements in lung SBRT? Phys Med 2017;44:150-6. [PMID: 27914779 DOI: 10.1016/j.ejmp.2016.11.114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
487 Cui Y, Guo G. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. Int J Mol Sci 2016;17:E1942. [PMID: 27869779 DOI: 10.3390/ijms17111942] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 9.9] [Reference Citation Analysis]
488 Hong JC, Salama JK. The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? Cancer Treat Rev 2017;52:22-32. [PMID: 27886588 DOI: 10.1016/j.ctrv.2016.11.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
489 Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH, Wang X, Thames H, Krishnan S. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys 2017;97:323-32. [PMID: 28068240 DOI: 10.1016/j.ijrobp.2016.10.046] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 7.9] [Reference Citation Analysis]
490 Hammers H. Immunotherapy in kidney cancer: the past, present, and future. Current Opinion in Urology 2016;26:543-7. [DOI: 10.1097/mou.0000000000000338] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
491 Cirincione R, Di Maggio FM, Forte GI, Minafra L, Bravatà V, Castiglia L, Cavalieri V, Borasi G, Russo G, Lio D. High-Intensity Focused Ultrasound- and Radiation Therapy-Induced Immuno-Modulation: Comparison and Potential Opportunities. Ultrasound Med Biol. 2017;43:398-411. [PMID: 27780661 DOI: 10.1016/j.ultrasmedbio.2016.09.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
492 Ascierto PA, Ascierto ML, Formenti S, Gnjatic S, Hammers H, Hirsh V, Kiessling R, Melero I, Nanda R, Pawelec G, Pignata S, Romero P, Speiser DE, Fox BA, Marincola FM. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015. j immunotherapy cancer 2016;4. [DOI: 10.1186/s40425-016-0168-3] [Reference Citation Analysis]
493 D'Souza NM, Fang P, Logan J, Yang J, Jiang W, Li J. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol 2016;6:212. [PMID: 27774435 DOI: 10.3389/fonc.2016.00212] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
494 Jamorabo DS, Lin SH, Jabbour SK. Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions. Seminars in Radiation Oncology 2016;26:307-19. [DOI: 10.1016/j.semradonc.2016.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
495 Gridelli C, Ascierto PA, Barberis MC, Felip E, Garon EB, O'brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opin Biol Ther 2016;16:1479-89. [PMID: 27650132 DOI: 10.1080/14712598.2016.1234602] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
496 Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51. [PMID: 27660705 DOI: 10.1186/s40425-016-0156-7] [Cited by in Crossref: 261] [Cited by in F6Publishing: 278] [Article Influence: 37.3] [Reference Citation Analysis]
497 Döscher J, Busch CJ, Schuler PJ, Laban S. [Immunotherapy for HNSCC : Quo vadis?]. HNO 2016;64:700-7. [PMID: 27624904 DOI: 10.1007/s00106-016-0241-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
498 Qin R, Olson A, Singh B, Thomas S, Wolf S, Bhavsar NA, Hanks BA, Salama JK, Salama AK. Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. International Journal of Radiation Oncology*Biology*Physics 2016;96:72-7. [DOI: 10.1016/j.ijrobp.2016.04.017] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
499 Reardon DA, Gilbert MR, Wick W, Liau L. Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol 2015;17 Suppl 7:vii32-40. [PMID: 26516225 DOI: 10.1093/neuonc/nov178] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
500 Hill RP. The changing paradigm of tumour response to irradiation. Br J Radiol 2017;90:20160474. [PMID: 27416998 DOI: 10.1259/bjr.20160474] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
501 Lin Y, Kuo H, Tseng L, Qiu J, Chang F, Lin C. Complete remission of relapsed cervical cancer through immunochemoradiotherapy: Two case reports and three proposed mechanism. Gynecology and Minimally Invasive Therapy 2016;5:127-131. [DOI: 10.1016/j.gmit.2016.01.008] [Reference Citation Analysis]
502 Yuan Y. Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb Perspect Med 2016;6:a026583. [PMID: 27481837 DOI: 10.1101/cshperspect.a026583] [Cited by in Crossref: 132] [Cited by in F6Publishing: 140] [Article Influence: 18.9] [Reference Citation Analysis]
503 Fokas E, Rödel C. Targeted agents in GI radiotherapy: Clinical efficacy and side effects. Best Pract Res Clin Gastroenterol 2016;30:537-49. [PMID: 27644903 DOI: 10.1016/j.bpg.2016.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
504 Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, Kitchen M, Köller M, Kollaritsch H, Kundi M, Lassmann H, Mutz I, Pickl WF, Riedl E, Sibilia M, Thalhammer F, Tucek B, Zenz W, Zwiauer K. [Guidelines for vaccination of immunocompromised individuals]. Wien Klin Wochenschr 2016;128 Suppl 4:337-76. [PMID: 27457874 DOI: 10.1007/s00508-016-1033-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
505 Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology 2016;5:e1214790. [PMID: 27757313 DOI: 10.1080/2162402X.2016.1214790] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
506 Habets TH, Oth T, Houben AW, Huijskens MJ, Senden-Gijsbers BL, Schnijderberg MC, Brans B, Dubois LJ, Lambin P, De Saint-Hubert M, Germeraad WT, Tilanus MG, Mottaghy FM, Bos GM, Vanderlocht J. Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS One 2016;11:e0159515. [PMID: 27427766 DOI: 10.1371/journal.pone.0159515] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
507 Michelle Xu M, Pu Y, Weichselbaum RR, Fu YX. Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene 2017;36:585-92. [PMID: 27425593 DOI: 10.1038/onc.2016.231] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
508 Kao J, Timmins J, Ozao-Choy J, Packer S. Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. Oncol Lett 2016;12:2139-44. [PMID: 27602153 DOI: 10.3892/ol.2016.4851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
509 Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer 2016;115:252-60. [PMID: 27380136 DOI: 10.1038/bjc.2016.166] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
510 Makinde AY, Eke I, Aryankalayil MJ, Ahmed MM, Coleman CN. Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy. Semin Radiat Oncol 2016;26:254-60. [PMID: 27619247 DOI: 10.1016/j.semradonc.2016.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
511 Eckert F, Schmitt J, Zips D, Krueger MA, Pichler BJ, Gillies SD, Strittmatter W, Handgretinger R, Schilbach K. Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. Cancer Immunol Immunother 2016;65:1003-13. [PMID: 27376889 DOI: 10.1007/s00262-016-1863-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
512 Naghavi AO, Strom TJ, Ahmed KA, Echevarria MI, Abuodeh YA, Venkat PS, Frakes JM, Harrison LB, Trotti AM, Caudell JJ. Management of Oropharyngeal Cancer in the HPV Era. Cancer Control 2016;23:197-207. [DOI: 10.1177/107327481602300302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
513 Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P. Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol 2016;120:1-12. [PMID: 27345592 DOI: 10.1016/j.radonc.2016.06.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
514 Kumar S, Singh RK, Meena R. Emerging targets for radioprotection and radiosensitization in radiotherapy. Tumor Biol 2016;37:11589-609. [DOI: 10.1007/s13277-016-5117-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
515 Asmar R, Rizvi NA. Immunotherapy for Advanced Lung Cancer. Cancer J 2015;21:383-91. [PMID: 26389763 DOI: 10.1097/PPO.0000000000000151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
516 McCaughan GJ, Fulham MJ, Mahar A, Soper J, Hong AM, Stalley PD, Tattersall MH, Bhadri VA. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol 2016;9:48. [PMID: 27259563 DOI: 10.1186/s13045-016-0278-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
517 Assmann N, Finlay DK. Metabolic regulation of immune responses: therapeutic opportunities. J Clin Invest 2016;126:2031-9. [PMID: 27249676 DOI: 10.1172/JCI83005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 9.6] [Reference Citation Analysis]
518 Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand-break repair in higher eukaryotes and its role in genomic instability and cancer: Cell cycle and proliferation-dependent regulation. Seminars in Cancer Biology 2016;37-38:51-64. [DOI: 10.1016/j.semcancer.2016.03.003] [Cited by in Crossref: 167] [Cited by in F6Publishing: 178] [Article Influence: 23.9] [Reference Citation Analysis]
519 Lee SJ, Yang A, Wu TC, Hung CF. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol 2016;27:e51. [PMID: 27329199 DOI: 10.3802/jgo.2016.27.e51] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 10.3] [Reference Citation Analysis]
520 Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016;9:47. [PMID: 27234522 DOI: 10.1186/s13045-016-0277-y] [Cited by in Crossref: 208] [Cited by in F6Publishing: 235] [Article Influence: 29.7] [Reference Citation Analysis]
521 Tiffen JC, Gallagher SJ, Tseng HY, Filipp FV, Fazekas de St. Groth B, Hersey P. EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res 2016;29:500-7. [PMID: 27063195 DOI: 10.1111/pcmr.12481] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
522 Morris ZS, Saha S, Magnuson WJ, Morris BA, Borkenhagen JF, Ching A, Hirose G, McMurry V, Francis DM, Harari PM, Chappell R, Tsuji S, Ritter MA. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer 2016;122:2487-95. [PMID: 27203227 DOI: 10.1002/cncr.30079] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
523 Napolitano M, D'Alterio C, Cardone E, Trotta AM, Pecori B, Rega D, Pace U, Scala D, Scognamiglio G, Tatangelo F, Cacciapuoti C, Pacelli R, Delrio P, Scala S. Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget 2015;6:8261-70. [PMID: 25823653 DOI: 10.18632/oncotarget.3014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
524 Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-cao M, Altavilla G, Rosell R. Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Review of Respiratory Medicine 2016;10:781-98. [DOI: 10.1080/17476348.2016.1182866] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
525 Ménager J, Gorin JB, Fichou N, Gouard S, Morgenstern A, Bruchertseifer F, Davodeau F, Kraeber-Bodéré F, Chérel M, Gaschet J, Guilloux Y. [Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity]. Med Sci (Paris) 2016;32:362-9. [PMID: 27137693 DOI: 10.1051/medsci/20163204014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
526 Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016;12:2219-31. [PMID: 27135835 DOI: 10.1080/21645515.2016.1175694] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
527 Lehman M. Improving Therapeutic Outcomes in Non-small Cell Lung Cancer not Suitable for Curative Intent Therapy — A Review of the Role of Radiation Therapy in an Era of Increasing Systemic Therapy Options. Clinical Oncology 2016;28:327-33. [DOI: 10.1016/j.clon.2015.11.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
528 Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med 2016;4:118. [PMID: 27127771 DOI: 10.21037/atm.2016.01.32] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 6.3] [Reference Citation Analysis]
529 Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B. Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel). 2016;11:108-115. [PMID: 27239172 DOI: 10.1159/000445335] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
530 Regal JF, Dornfeld KJ, Fleming SD. Radiotherapy: killing with complement. Ann Transl Med 2016;4:94. [PMID: 27047953 DOI: 10.21037/atm.2015.12.46] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
531 Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016;9:1899-920. [PMID: 27099521 DOI: 10.2147/OTT.S95101] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
532 Wu L, Wu MO, De la Maza L, Yun Z, Yu J, Zhao Y, Cho J, de Perrot M. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget. 2015;6:12468-12480. [PMID: 25980578 DOI: 10.18632/oncotarget.3487] [Cited by in Crossref: 52] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
533 Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer 2016;4:15. [PMID: 26981245 DOI: 10.1186/s40425-016-0118-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
534 Vaupel P, Multhoff G. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities. Strahlenther Onkol 2016;192:279-87. [PMID: 26961686 DOI: 10.1007/s00066-016-0948-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
535 Achyut BR, Arbab AS. Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther 2016;9:1047-55. [PMID: 27042097 DOI: 10.2147/OTT.S102907] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
536 Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A, Staehler M, Onishi H, Wersall P, Nomiya T, Lo SS. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncology 2016;12:637-45. [DOI: 10.2217/fon.16.2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
537 Salama AKS, Postow MA, Salama JK. Irradiation and immunotherapy: From concept to the clinic: Radiation and Immunotherapy. Cancer 2016;122:1659-71. [DOI: 10.1002/cncr.29889] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
538 Malik A, Sultana M, Qazi A, Qazi MH, Parveen G, Waquar S, Ashraf AB, Rasool M. Role of Natural Radiosensitizers and Cancer Cell Radioresistance: An Update. Anal Cell Pathol (Amst) 2016;2016:6146595. [PMID: 26998418 DOI: 10.1155/2016/6146595] [Cited by in Crossref: 34] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
539 Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG. Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol 2016;6:24. [PMID: 26909338 DOI: 10.3389/fonc.2016.00024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
540 Gordon JJ. On the feasibility of extracting dose–response curves from clinical DVH data using correlation and regression analysis. Biomed Phys Eng Express 2016;2:015018. [DOI: 10.1088/2057-1976/2/1/015018] [Reference Citation Analysis]
541 Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget 2015;6:8491-524. [PMID: 25940699 DOI: 10.18632/oncotarget.3455] [Cited by in Crossref: 174] [Cited by in F6Publishing: 194] [Article Influence: 24.9] [Reference Citation Analysis]
542 Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology 2016;28:64-72. [DOI: 10.1016/j.smim.2015.11.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
543 Wu CT, Chen WC, Chang YH, Lin WY, Chen MF. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep. 2016;6:19740. [PMID: 26804478 DOI: 10.1038/srep19740] [Cited by in Crossref: 120] [Cited by in F6Publishing: 123] [Article Influence: 17.1] [Reference Citation Analysis]
544 Adjiri A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther 2016;4:17-33. [PMID: 28261638 DOI: 10.1007/s40487-015-0015-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
545 Moraes FY, Taunk NK, Marta GN, Suh JH, Yamada Y. The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases. Oncologist 2016;21:244-51. [PMID: 26764249 DOI: 10.1634/theoncologist.2015-0293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
546 Schölch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 2015;6:4663-76. [PMID: 25609199 DOI: 10.18632/oncotarget.3081] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
547 Callahan MK, Flaherty CR, Postow MA. Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer Treat Res 2016;167:231-50. [PMID: 26601865 DOI: 10.1007/978-3-319-22539-5_9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
548 Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA Cancer Vaccines. Recent Results Cancer Res 2016;209:61-85. [PMID: 28101688 DOI: 10.1007/978-3-319-42934-2_5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
549 Pasinetti N, Pirtoli L, Buglione M, Triggiani L, Borghetti P, Tini P, Magrini SM. From Molecular to Clinical Radiation Biology of Glioblastoma. Current Clinical Pathology 2016. [DOI: 10.1007/978-3-319-28305-0_17] [Reference Citation Analysis]
550 Schoenhals JE, Brooks ED, Cortez MA, Seyedin SN, Niknam S, Wang X, Cadena AP, Li XS, Gomez DR, Liao Z, Welsh JW. Translational Research and Immunotherapy in Lung Cancer. Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies 2016. [DOI: 10.1007/978-3-319-28761-4_12] [Reference Citation Analysis]
551 Lasek W, Jakóbisiak M. Antitumor Effects of IL-12 in Preclinical Studies. Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology 2016. [DOI: 10.1007/978-3-319-46906-5_2] [Reference Citation Analysis]
552 Lim S, Hong M, Ahn S, Choi Y, Kim K, Oh D, Ahn Y, Jung S, Ahn M, Park K, Zo J, Shim Y, Sun J. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. European Journal of Cancer 2016;52:1-9. [DOI: 10.1016/j.ejca.2015.09.019] [Cited by in Crossref: 88] [Cited by in F6Publishing: 98] [Article Influence: 12.6] [Reference Citation Analysis]
553 Pitt JM, Hannani D, Vétizou M, Zitvogel L. Combining Immunotherapies with Standard Therapies in the Treatment of Cancer. Encyclopedia of Immunobiology 2016. [DOI: 10.1016/b978-0-12-374279-7.17024-9] [Reference Citation Analysis]
554 Tinganelli W, Durante M, Helm A. Clinical Evidence and Radiobiological Background of Particle Radiation Therapy. Current Clinical Pathology 2016. [DOI: 10.1007/978-3-319-28305-0_5] [Reference Citation Analysis]
555 Cooper B, Vatner R, Golden E, Silverman J, Formenti S. The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. Current Clinical Pathology 2016. [DOI: 10.1007/978-3-319-28305-0_10] [Reference Citation Analysis]
556 Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer 2015;3:50. [PMID: 26672895 DOI: 10.1186/s40425-015-0095-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 8.9] [Reference Citation Analysis]
557 Guazzelli A, Hussain M, Krstic-demonacos M, Mutti L. Tremelimumab for the treatment of malignant mesothelioma. Expert Opinion on Biological Therapy 2015;15:1819-29. [DOI: 10.1517/14712598.2015.1116515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
558 Ghodadra A, Bhatt S, Camacho JC, Kim HS. Abscopal Effects and Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol 2016;39:1076-80. [PMID: 26662290 DOI: 10.1007/s00270-015-1259-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
559 Huang Y, Chen W, Teh BS, Butler EB. Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. J Radiat Oncol 2015;4:365-75. [DOI: 10.1007/s13566-015-0240-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
560 Naghavi AO, Johnstone PA, Kim S. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. Curr Probl Cancer 2016;40:38-67. [PMID: 26656977 DOI: 10.1016/j.currproblcancer.2015.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
561 Farach A, Farach-carson MC, Butler EB, Chang JC, Teh BS. The role of combined radiation and immunotherapy in breast cancer treatment. J Radiat Oncol 2015;4:347-54. [DOI: 10.1007/s13566-015-0216-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
562 Kumari A, Simon SS, Moody TD, Garnett-Benson C. Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol 2016;12:239-56. [PMID: 26621553 DOI: 10.2217/fon.15.300] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
563 Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13:143-158. [PMID: 26598942 DOI: 10.1038/nrclinonc.2015.209] [Cited by in Crossref: 571] [Cited by in F6Publishing: 610] [Article Influence: 71.4] [Reference Citation Analysis]
564 Lan C, Heindl A, Huang X, Xi S, Banerjee S, Liu J, Yuan Y. Quantitative histology analysis of the ovarian tumour microenvironment. Sci Rep 2015;5:16317. [PMID: 26573438 DOI: 10.1038/srep16317] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
565 Kim BM, Hong Y, Lee S, Liu P, Lim JH, Lee YH, Lee TH, Chang KT, Hong Y. Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. Int J Mol Sci 2015;16:26880-913. [PMID: 26569225 DOI: 10.3390/ijms161125991] [Cited by in Crossref: 120] [Cited by in F6Publishing: 134] [Article Influence: 15.0] [Reference Citation Analysis]
566 Gorin JB, Gouard S, Ménager J, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Guilloux Y, Chérel M, Davodeau F, Gaschet J. Alpha Particles Induce Autophagy in Multiple Myeloma Cells. Front Med (Lausanne) 2015;2:74. [PMID: 26539436 DOI: 10.3389/fmed.2015.00074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
567 Hanna GG, Coyle VM, Prise KM. Immune modulation in advanced radiotherapies: Targeting out-of-field effects. Cancer Letters 2015;368:246-51. [DOI: 10.1016/j.canlet.2015.04.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
568 Hellweg CE. The Nuclear Factor κB pathway: A link to the immune system in the radiation response. Cancer Letters 2015;368:275-89. [DOI: 10.1016/j.canlet.2015.02.019] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 11.5] [Reference Citation Analysis]
569 Rivalland G, Loveland B, Mitchell P. Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Expert Opin Biol Ther 2015;15:1773-87. [PMID: 26453294 DOI: 10.1517/14712598.2015.1088519] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
570 Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015;15:457-72. [PMID: 26205340 DOI: 10.1038/nrc3973] [Cited by in Crossref: 464] [Cited by in F6Publishing: 485] [Article Influence: 58.0] [Reference Citation Analysis]
571 Metro G, Chiari R, Ricciuti B, Rebonato A, Lupattelli M, Gori S, Bennati C, Castrioto C, Floridi P, Minotti V, Chiarini P, Crinò L. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opin Pharmacother 2015;16:2601-13. [PMID: 26439599 DOI: 10.1517/14656566.2015.1094056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
572 Ngiow SF, McArthur GA, Smyth MJ. Radiotherapy complements immune checkpoint blockade. Cancer Cell. 2015;27:437-438. [PMID: 25873170 DOI: 10.1016/j.ccell.2015.03.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
573 Pujol J, Vansteenkiste JF, Pas TMD, Atanackovic D, Reck M, Thomeer M, Douillard J, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2015;10:1458-67. [DOI: 10.1097/jto.0000000000000653] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
574 Bastianpillai C, Petrides N, Shah T, Guillaumier S, Ahmed HU, Arya M. Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. Tumour Biol 2015;36:9137-46. [PMID: 26423402 DOI: 10.1007/s13277-015-4126-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
575 Maley CC, Koelble K, Natrajan R, Aktipis A, Yuan Y. An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Breast Cancer Res 2015;17:131. [PMID: 26395345 DOI: 10.1186/s13058-015-0638-4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
576 Paniccia A, Merkow J, Edil BH, Zhu Y. Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res 2015;27:376-91. [PMID: 26361407 DOI: 10.3978/j.issn.1000-9604.2015.05.01] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
577 Price JG, Idoyaga J, Salmon H, Hogstad B, Bigarella CL, Ghaffari S, Leboeuf M, Merad M. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat Immunol 2015;16:1060-8. [PMID: 26343536 DOI: 10.1038/ni.3270] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 11.8] [Reference Citation Analysis]
578 Maeda A, Kulbatski I, Dacosta RS. Emerging Applications for Optically Enabled Intravital Microscopic Imaging in Radiobiology. Mol Imaging 2015;14:7290.2015.00022. [DOI: 10.2310/7290.2015.00022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
579 Freeman-keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer: Clinical experience and future directions. Pharmacology & Therapeutics 2015;153:1-9. [DOI: 10.1016/j.pharmthera.2015.05.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
580 Zappasodi R, Merghoub T. Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy 2015;7:981-97. [DOI: 10.2217/imt.15.64] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
581 Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2:831-838. [PMID: 25187273 DOI: 10.1158/2326-6066.cir-14-0069] [Cited by in Crossref: 210] [Cited by in F6Publishing: 234] [Article Influence: 26.3] [Reference Citation Analysis]
582 Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 2015;7:967-80. [PMID: 26310908 DOI: 10.2217/imt.15.65] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 7.9] [Reference Citation Analysis]
583 Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365-372. [PMID: 24563870 DOI: 10.1158/2326-6066.cir-13-0115] [Cited by in Crossref: 473] [Cited by in F6Publishing: 505] [Article Influence: 59.1] [Reference Citation Analysis]
584 Garnett-Benson C, Hodge JW, Gameiro SR. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol 2015;25:46-53. [PMID: 25481266 DOI: 10.1016/j.semradonc.2014.07.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
585 Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015;25:11-7. [PMID: 25481261 DOI: 10.1016/j.semradonc.2014.07.005] [Cited by in Crossref: 250] [Cited by in F6Publishing: 276] [Article Influence: 31.3] [Reference Citation Analysis]
586 Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Letters 2015;365:23-9. [DOI: 10.1016/j.canlet.2015.05.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
587 Callahan MK, Wolchok JD. Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in Oncology 2015;42:573-86. [DOI: 10.1053/j.seminoncol.2015.05.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
588 Baxevanis CN, Perez SA. Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines (Basel) 2015;3:597-619. [PMID: 26350597 DOI: 10.3390/vaccines3030597] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
589 Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015;6:368. [PMID: 26284063 DOI: 10.3389/fimmu.2015.00368] [Cited by in Crossref: 255] [Cited by in F6Publishing: 295] [Article Influence: 31.9] [Reference Citation Analysis]
590 Kokate RA, Thamake SI, Chaudhary P, Mott B, Raut S, Vishwanatha JK, Jones HP. Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles. Nanomedicine (Lond) 2015;10:915-29. [PMID: 25867857 DOI: 10.2217/nnm.14.144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
591 Rekers NH, Zegers CM, Yaromina A, Lieuwes NG, Biemans R, Senden-Gijsbers BL, Losen M, Van Limbergen EJ, Germeraad WT, Neri D, Dubois L, Lambin P. Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiother Oncol 2015;116:438-42. [PMID: 26138057 DOI: 10.1016/j.radonc.2015.06.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
592 Ménager J, Gorin JB, Maurel C, Drujont L, Gouard S, Louvet C, Chérel M, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Davodeau F, Gaschet J, Guilloux Y. Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction. PLoS One 2015;10:e0130249. [PMID: 26098691 DOI: 10.1371/journal.pone.0130249] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
593 Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795-803. [PMID: 26095785 DOI: 10.1016/s1470-2045(15)00054-6] [Cited by in Crossref: 417] [Cited by in F6Publishing: 382] [Article Influence: 52.1] [Reference Citation Analysis]
594 Yuen NK, Li CS, Monjazeb AM, Borys D, Bold RJ, Canter RJ. Older age impacts radiotherapy-related outcomes in soft tissue sarcoma. J Surg Res 2015;199:494-504. [PMID: 26163324 DOI: 10.1016/j.jss.2015.06.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
595 Goel G, Sun W. Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014;33:445-57. [PMID: 25189717 DOI: 10.5732/cjc.014.10123] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
596 Pennock GK, Chow LQ. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist. 2015;20:812-822. [PMID: 26069281 DOI: 10.1634/theoncologist.2014-0422] [Cited by in Crossref: 145] [Cited by in F6Publishing: 158] [Article Influence: 18.1] [Reference Citation Analysis]
597 Peske JD, Woods AB, Engelhard VH. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Adv Cancer Res 2015;128:263-307. [PMID: 26216636 DOI: 10.1016/bs.acr.2015.05.001] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 10.6] [Reference Citation Analysis]
598 Beavis PA, Slaney CY, Kershaw MH, Neeson PJ, Darcy PK. Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy 2015;7:499-512. [DOI: 10.2217/imt.15.16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
599 Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015;4:e1046028. [PMID: 26451318 DOI: 10.1080/2162402X.2015.1046028] [Cited by in Crossref: 165] [Cited by in F6Publishing: 151] [Article Influence: 20.6] [Reference Citation Analysis]
600 De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology 2015;4:e1042198. [PMID: 26464810 DOI: 10.1080/2162402X.2015.1042198] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
601 Ree AH, Redalen KR. Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol 2015;88:20150009. [PMID: 25989697 DOI: 10.1259/bjr.20150009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
602 Le QT, Shirato H, Giaccia AJ, Koong AC. Emerging Treatment Paradigms in Radiation Oncology. Clin Cancer Res 2015;21:3393-401. [PMID: 25991820 DOI: 10.1158/1078-0432.CCR-14-1191] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
603 Gorchs L, Hellevik T, Bruun JA, Camilio KA, Al-Saad S, Stuge TB, Martinez-Zubiaurre I. Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Front Oncol 2015;5:87. [PMID: 26029659 DOI: 10.3389/fonc.2015.00087] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
604 Furlan C. Microenvironment and radiation therapy. Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 1) 2015. [DOI: 10.2217/fmeb2014.14.37] [Reference Citation Analysis]
605 Apetoh L, Ladoire S, Coukos G, Ghiringhelli F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 2015;26:1813-23. [PMID: 25922066 DOI: 10.1093/annonc/mdv209] [Cited by in Crossref: 159] [Cited by in F6Publishing: 174] [Article Influence: 19.9] [Reference Citation Analysis]
606 Chiang CL, Coukos G, Kandalaft LE. Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) 2015;3:344-72. [PMID: 26343191 DOI: 10.3390/vaccines3020344] [Cited by in Crossref: 157] [Cited by in F6Publishing: 161] [Article Influence: 19.6] [Reference Citation Analysis]
607 Chow KK, Hara W, Lim M, Li G. Combining immunotherapy with radiation for the treatment of glioblastoma. J Neurooncol 2015;123:459-64. [PMID: 25877468 DOI: 10.1007/s11060-015-1762-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
608 Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res 2015;21:3727-39. [PMID: 25869387 DOI: 10.1158/1078-0432.CCR-14-2824] [Cited by in Crossref: 273] [Cited by in F6Publishing: 296] [Article Influence: 34.1] [Reference Citation Analysis]
609 Elgström E, Eriksson SE, Ohlsson TG, Nilsson R, Tennvall J. Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model. EJNMMI Res 2015;5:3. [PMID: 25853009 DOI: 10.1186/s13550-014-0079-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
610 Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, Demaria S. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res 2015;75:2232-42. [PMID: 25858148 DOI: 10.1158/0008-5472.CAN-14-3511] [Cited by in Crossref: 336] [Cited by in F6Publishing: 352] [Article Influence: 42.0] [Reference Citation Analysis]
611 Golden EB, Formenti SC. Radiation therapy and immunotherapy: growing pains. Int J Radiat Oncol Biol Phys 2015;91:252-4. [PMID: 25636751 DOI: 10.1016/j.ijrobp.2014.09.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
612 Gaya A, Akle CA, Mudan S, Grange J. The Concept of Hormesis in Cancer Therapy - Is Less More? Cureus 2015;7:e261. [PMID: 26180685 DOI: 10.7759/cureus.261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
613 Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015;6:208-223. [PMID: 25830040 DOI: 10.3978/j.issn.2078-6891.2014.077] [Cited by in F6Publishing: 77] [Reference Citation Analysis]
614 Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014;33:641-55. [PMID: 24477411 DOI: 10.1007/s10555-013-9479-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
615 Patel MA, Kim JE, Ruzevick J, Lim M. Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World J Immunol 2015; 5(1): 1-15 [DOI: 10.5411/wji.v5.i1.1] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
616 Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 2015;7:280sr1-280sr1. [DOI: 10.1126/scitranslmed.3010274] [Cited by in Crossref: 120] [Cited by in F6Publishing: 123] [Article Influence: 15.0] [Reference Citation Analysis]
617 Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res 2014;3:53-63. [PMID: 25806281 DOI: 10.3978/j.issn.2218-6751.2014.01.01] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
618 Guo G, Cui Y. New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. J Immunother Cancer 2015;3:9. [PMID: 25806108 DOI: 10.1186/s40425-015-0053-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
619 Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: Optimal dose and fractionation. Cancer Lett 2015;368:185-90. [PMID: 25799953 DOI: 10.1016/j.canlet.2015.03.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
620 Horton JK, Blitzblau RC, Yoo S, Geradts J, Chang Z, Baker JA, Georgiade GS, Chen W, Siamakpour-Reihani S, Wang C, Broadwater G, Groth J, Palta M, Dewhirst M, Barry WT, Duffy EA, Chi JT, Hwang ES. Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. Int J Radiat Oncol Biol Phys 2015;92:846-55. [PMID: 26104938 DOI: 10.1016/j.ijrobp.2015.03.007] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
621 Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:85-96. [PMID: 25755681 DOI: 10.1177/1758834014567470] [Cited by in Crossref: 151] [Cited by in F6Publishing: 164] [Article Influence: 18.9] [Reference Citation Analysis]
622 Zhao H, Xie P, Li X, Zhu W, Sun X, Sun X, Chen X, Xing L, Yu J. A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer. Radiother Oncol 2015;114:351-6. [PMID: 25769379 DOI: 10.1016/j.radonc.2015.02.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
623 Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM. TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res 2015;3:518-25. [PMID: 25716473 DOI: 10.1158/2326-6066.CIR-14-0232] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 19.0] [Reference Citation Analysis]
624 Di Maggio FM, Minafra L, Forte GI, Cammarata FP, Lio D, Messa C, Gilardi MC, Bravatà V. Portrait of inflammatory response to ionizing radiation treatment. J Inflamm (Lond) 2015;12:14. [PMID: 25705130 DOI: 10.1186/s12950-015-0058-3] [Cited by in Crossref: 156] [Cited by in F6Publishing: 166] [Article Influence: 19.5] [Reference Citation Analysis]
625 Zheng Y, Dou Y, Duan L, Cong C, Gao A, Lai Q, Sun Y. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol. 2015;294:54-59. [PMID: 25687508 DOI: 10.1016/j.cellimm.2015.02.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
626 Soukup K, Wang X. Radiation meets immunotherapy - a perfect match in the era of combination therapy? Int J Radiat Biol 2015;91:299-305. [PMID: 25630486 DOI: 10.3109/09553002.2014.995383] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
627 Finkelstein SE, Salenius S, Mantz CA, Shore ND, Fernandez EB, Shulman J, Myslicki FA, Agassi AM, Rotterman Y, Devries T, Sims R. Combining Immunotherapy and Radiation for Prostate Cancer. Clinical Genitourinary Cancer 2015;13:1-9. [DOI: 10.1016/j.clgc.2014.09.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
628 van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans AM, De Ruysscher D, Laurent J, Tighe R, Haanen J, Quaratino S. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med 2015;13:32. [PMID: 25622640 DOI: 10.1186/s12967-015-0397-0] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 8.3] [Reference Citation Analysis]
629 Gorin JB, Ménager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Chérel M, Davodeau F, Gaschet J. Antitumor immunity induced after α irradiation. Neoplasia 2014;16:319-28. [PMID: 24862758 DOI: 10.1016/j.neo.2014.04.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
630 Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33:1974-1982. [PMID: 25605845 DOI: 10.1200/jco.2014.59.4358] [Cited by in Crossref: 1664] [Cited by in F6Publishing: 1782] [Article Influence: 208.0] [Reference Citation Analysis]
631 Seyedin SN, Tang C, Welsh JW. Author's view: radiation and immunotherapy as systemic therapy for solid tumors. Oncoimmunology. 2015;4:e986402. [PMID: 25949899 DOI: 10.4161/2162402x.2014.986402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
632 Adkins I, Fucikova J, Garg AD, Agostinis P, Špíšek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 2014;3:e968434. [PMID: 25964865 DOI: 10.4161/21624011.2014.968434] [Cited by in Crossref: 118] [Cited by in F6Publishing: 126] [Article Influence: 14.8] [Reference Citation Analysis]
633 Seyedin S, Welsh J. Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy. Breast Diseases: A Year Book Quarterly 2015;26:82-83. [DOI: 10.1016/j.breastdis.2015.01.026] [Reference Citation Analysis]
634 Formenti SC. Introduction. Seminars in Radiation Oncology 2015;25:1-3. [DOI: 10.1016/j.semradonc.2014.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
635 Formenti SC. Combining radiation therapy with immunotherapy: clinical translation. J Transl Med 2015;13:K10. [DOI: 10.1186/1479-5876-13-s1-k10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
636 De Tullio G, Strippoli S, Angarano R, De Fazio V, Sgherza N, Negri A, Albano A, Iacopino P, Guarini A, Guida M. αβ-Double Negative CD4/CD8 (CD56) T cell (DNTs) in metastatic melanoma: basal frequency and behaviour during Ipilimumab treatment. Preliminary evaluations. J Transl Med 2015;13:O10. [DOI: 10.1186/1479-5876-13-s1-o10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
637 Aryan Z, Mellstedt H, Rezaei N. Cancer Immunotherapy Confers a Global Benefit. Cancer Immunology 2015. [DOI: 10.1007/978-3-662-46410-6_1] [Reference Citation Analysis]
638 Thyagarajan K, Chatterjee S, Kesarwani P, Nishimura MI, Mehrotra S. Quality of CTL Therapies: A Changing Landscape. Resistance to Targeted Anti-Cancer Therapeutics 2015. [DOI: 10.1007/978-3-319-17807-3_14] [Reference Citation Analysis]
639 Lawrence YR, Dicker AP. Radiation therapy and the immune system: learning to live together. Future Oncol 2014;10:777-80. [PMID: 24799058 DOI: 10.2217/fon.14.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
640 Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncol 2014;10:761-74. [PMID: 24799057 DOI: 10.2217/fon.14.40] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
641 Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015;3:345-355. [PMID: 25527358 DOI: 10.1158/2326-6066.cir-14-0196] [Cited by in Crossref: 407] [Cited by in F6Publishing: 434] [Article Influence: 45.2] [Reference Citation Analysis]
642 Gorin JB, Guilloux Y, Morgenstern A, Chérel M, Davodeau F, Gaschet J. Using α radiation to boost cancer immunity? Oncoimmunology 2014;3:e954925. [PMID: 25941605 DOI: 10.4161/21624011.2014.954925] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
643 Fernández-garcía EM, Vera-badillo FE, Perez-valderrama B, Matos-pita AS, Duran I. Immunotherapy in prostate cancer: review of the current evidence. Clin Transl Oncol 2015;17:339-57. [DOI: 10.1007/s12094-014-1259-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
644 Gultekin M, Yazici O, Eren G, Yuce D, Aksoy S, Ozisik Y, Guler N, Yazici G, Hurmuz P, Yildiz F, Altundag K, Gurkaynak M. Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma. The Breast 2014;23:775-83. [DOI: 10.1016/j.breast.2014.08.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
645 Graves DB. Oxy-nitroso shielding burst model of cold atmospheric plasma therapeutics. Clinical Plasma Medicine 2014;2:38-49. [DOI: 10.1016/j.cpme.2014.11.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 9.0] [Reference Citation Analysis]
646 Agassi AM, Myslicki FA, Shulman JM, Rotterman Y, Dosoretz DE, Fernandez E, Mantz CA, Finkelstein SE. The promise of combining radiation therapy and immunotherapy: morbidity and toxicity. Future Oncology 2014;10:2319-28. [DOI: 10.2217/fon.14.188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
647 Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014;4:325. [PMID: 25506582 DOI: 10.3389/fonc.2014.00325] [Cited by in Crossref: 157] [Cited by in F6Publishing: 173] [Article Influence: 17.4] [Reference Citation Analysis]
648 Xia W, Wang J, Xu Y, Jiang F, Xu L. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. J Thorac Dis 2014;6:1513-20. [PMID: 25364531 DOI: 10.3978/j.issn.2072-1439.2014.08.17] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
649 Finocchiaro G, Pellegatta S. Perspectives for immunotherapy in glioblastoma treatment. Current Opinion in Oncology 2014;26:608-14. [DOI: 10.1097/cco.0000000000000135] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
650 Wei L, Wei G, Jin S, Cong C, Huilin X, Pingpo M. Blocking HIF-1α following radiotherapy to prolong and enhance the immune effects of radiotherapy: a hypothesis. Med Sci Monit 2014;20:2106-8. [PMID: 25358601 DOI: 10.12659/MSM.891048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
651 Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiother Oncol 2014;113:35-40. [PMID: 25441058 DOI: 10.1016/j.radonc.2014.08.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
652 Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst 2014;106:dju329. [PMID: 25326640 DOI: 10.1093/jnci/dju329] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
653 Confino H, Hochman I, Efrati M, Schmidt M, Umansky V, Kelson I, Keisari Y. Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors. Cancer Immunol Immunother 2015;64:191-9. [PMID: 25326364 DOI: 10.1007/s00262-014-1626-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
654 Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014;14:748. [PMID: 25288198 DOI: 10.1186/1471-2407-14-748] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 8.6] [Reference Citation Analysis]
655 Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, Parisi E, Romeo A, Guidoboni M. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med 2014;12:262. [PMID: 25245327 DOI: 10.1186/s12967-014-0262-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
656 Heigener D, Reck M. Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 2015;15:69-83. [PMID: 25199617 DOI: 10.1586/14737140.2015.957187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
657 Blumenfeld P, Pfeffer RM, Symon Z, Den RB, Dicker AP, Raben D, Lawrence YR. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? Br J Cancer 2014;111:1305-9. [PMID: 25117813 DOI: 10.1038/bjc.2014.448] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
658 Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32:2902-2912. [PMID: 25113765 DOI: 10.1200/jco.2014.55.9567] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 7.1] [Reference Citation Analysis]
659 Morris ZS, Harari PM. Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 2014;32:2886-93. [PMID: 25113770 DOI: 10.1200/JCO.2014.55.1366] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 7.6] [Reference Citation Analysis]
660 Coleman CN, Lawrence TS, Kirsch DG. Enhancing the efficacy of radiation therapy: premises, promises, and practicality. J Clin Oncol 2014;32:2832-5. [PMID: 25113766 DOI: 10.1200/JCO.2014.57.3865] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
661 Giaccia AJ. Molecular radiobiology: the state of the art. J Clin Oncol 2014;32:2871-8. [PMID: 25113768 DOI: 10.1200/JCO.2014.57.2776] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
662 de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. J Transl Med 2014;12:209. [PMID: 25053129 DOI: 10.1186/1479-5876-12-209] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
663 Aryankalayil MJ, Makinde AY, Gameiro SR, Hodge JW, Rivera-Solis PP, Palayoor ST, Ahmed MM, Coleman CN. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res 2014;182:139-48. [PMID: 25003313 DOI: 10.1667/RR13731.1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
664 Almo SC, Guha C. Considerations for combined immune checkpoint modulation and radiation treatment. Radiat Res. 2014;182:230-238. [PMID: 25003312 DOI: 10.1667/rr13667.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
665 Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 2014;89:1084-91. [PMID: 25035212 DOI: 10.1016/j.ijrobp.2014.04.025] [Cited by in Crossref: 195] [Cited by in F6Publishing: 192] [Article Influence: 21.7] [Reference Citation Analysis]
666 McDermott D, Lebbé C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014;40:1056-64. [PMID: 25060490 DOI: 10.1016/j.ctrv.2014.06.012] [Cited by in Crossref: 138] [Cited by in F6Publishing: 150] [Article Influence: 15.3] [Reference Citation Analysis]
667 Palmer JD, Zaorsky NG, Witek M, Lu B. Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis 2014;6:387-98. [PMID: 24688783 DOI: 10.3978/j.issn.2072-1439.2013.12.04] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
668 Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 2014;182:170-81. [PMID: 24937779 DOI: 10.1667/RR13500.1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 7.0] [Reference Citation Analysis]
669 Durante M. New challenges in high-energy particle radiobiology. Br J Radiol 2014;87:20130626. [PMID: 24198199 DOI: 10.1259/bjr.20130626] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 10.0] [Reference Citation Analysis]
670 Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S, Raab H, Sauer R, Wittekind C, Rödel C. Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial. JCO 2014;32:1554-62. [DOI: 10.1200/jco.2013.54.3769] [Cited by in Crossref: 256] [Cited by in F6Publishing: 284] [Article Influence: 28.4] [Reference Citation Analysis]
671 Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys 2014;88:1188-95. [PMID: 24661671 DOI: 10.1016/j.ijrobp.2013.12.043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
672 Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 2014;88:986-97. [PMID: 24661650 DOI: 10.1016/j.ijrobp.2013.08.035] [Cited by in Crossref: 103] [Cited by in F6Publishing: 112] [Article Influence: 11.4] [Reference Citation Analysis]
673 Palayoor ST, John-Aryankalayil M, Makinde AY, Falduto MT, Magnuson SR, Coleman CN. Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation. Mol Cancer Res 2014;12:1002-15. [PMID: 24784841 DOI: 10.1158/1541-7786.MCR-13-0623] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
674 Gameiro SR, Ardiani A, Kwilas A, Hodge JW. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology 2014;3:e28643. [PMID: 25097803 DOI: 10.4161/onci.28643] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
675 Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014;3:e28518. [PMID: 25071979 DOI: 10.4161/onci.28518] [Cited by in Crossref: 322] [Cited by in F6Publishing: 345] [Article Influence: 35.8] [Reference Citation Analysis]
676 Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, Alongi F, Clerici E, Lobefalo F, Tozzi A. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9:91. [PMID: 24694067 DOI: 10.1186/1748-717x-9-91] [Cited by in Crossref: 64] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
677 Golden EB, Formenti SC. Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology 2014;3:e28133. [PMID: 24800177 DOI: 10.4161/onci.28133] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
678 Chen X, Liao C, Chu Q, Zhou G, Lin X, Li X, Lu H, Xu B, Yue Z. Dissecting the molecular mechanism of ionizing radiation-induced tissue damage in the feather follicle. PLoS One 2014;9:e89234. [PMID: 24586618 DOI: 10.1371/journal.pone.0089234] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
679 Tang C, Liao Z, Zhuang Y, Levy LB, Hung C, Li X, Krafft SP, Martel MK, Komaki R, Gomez DR. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol 2014;110:493-8. [PMID: 24560756 DOI: 10.1016/j.radonc.2014.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
680 Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer 2014;110:1472-80. [PMID: 24556625 DOI: 10.1038/bjc.2014.79] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
681 Kulzer L, Rubner Y, Deloch L, Allgäuer A, Frey B, Fietkau R, Dörrie J, Schaft N, Gaipl US. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol 2014;11:328-36. [PMID: 24512329 DOI: 10.3109/1547691X.2014.880533] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
682 Elgqvist J, Frost S, Pouget JP, Albertsson P. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol 2014;3:324. [PMID: 24459634 DOI: 10.3389/fonc.2013.00324] [Cited by in Crossref: 110] [Cited by in F6Publishing: 118] [Article Influence: 12.2] [Reference Citation Analysis]
683 Declerck S, Vansteenkiste J. Immunotherapy for lung cancer: ongoing clinical trials. Future Oncology 2014;10:91-105. [DOI: 10.2217/fon.13.166] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
684 Kirkpatrick JP, Kelsey CR, Palta M, Cabrera AR, Salama JK, Patel P, Perez BA, Lee J, Yin FF. Stereotactic body radiotherapy: a critical review for nonradiation oncologists. Cancer 2014;120:942-54. [PMID: 24382744 DOI: 10.1002/cncr.28515] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 5.4] [Reference Citation Analysis]
685 Saied A, Pillarisetty VG, Katz SC. Immunotherapy for solid tumors--a review for surgeons. J Surg Res 2014;187:525-35. [PMID: 24485876 DOI: 10.1016/j.jss.2013.12.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
686 Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59-68. [PMID: 24331154 DOI: 10.1016/s1470-2045(13)70510-2] [Cited by in Crossref: 328] [Cited by in F6Publishing: 382] [Article Influence: 32.8] [Reference Citation Analysis]
687 Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F, Rödel C, Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014;110:501-9. [PMID: 24129245 DOI: 10.1038/bjc.2013.640] [Cited by in Crossref: 212] [Cited by in F6Publishing: 218] [Article Influence: 21.2] [Reference Citation Analysis]
688 Demaria S, Vanpouille-Box C, Formenti SC, Adams S. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology. 2013;2:e25997. [PMID: 24404422 DOI: 10.4161/onci.25997] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
689 Frey B, Rubner Y, Kulzer L, Werthmöller N, Weiss EM, Fietkau R, Gaipl US. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 2014;63:29-36. [PMID: 24052136 DOI: 10.1007/s00262-013-1474-y] [Cited by in Crossref: 100] [Cited by in F6Publishing: 105] [Article Influence: 10.0] [Reference Citation Analysis]
690 Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends in Molecular Medicine 2013;19:565-82. [DOI: 10.1016/j.molmed.2013.05.007] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
691 Formenti SC, Demaria S. Successful clinical translation of preclinical combinations of radiation and immunotherapy. European Journal of Cancer Supplements 2013;11:270. [DOI: 10.1016/j.ejcsup.2013.07.040] [Reference Citation Analysis]
692 Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir Med 2013;1:551-63. [PMID: 24461616 DOI: 10.1016/S2213-2600(13)70159-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
693 Huber SM, Butz L, Stegen B, Klumpp D, Braun N, Ruth P, Eckert F. Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol 2013;4:212. [PMID: 23966948 DOI: 10.3389/fphys.2013.00212] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
694 Menzies AM, Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 2013;49:3229-41. [PMID: 23870385 DOI: 10.1016/j.ejca.2013.06.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
695 Alcorn S, Walker AJ, Gandhi N, Narang A, Wild AT, Hales RK, Herman JM, Song DY, Deweese TL, Antonarakis ES, Tran PT. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci 2013;14:14800-32. [PMID: 23863691 DOI: 10.3390/ijms140714800] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
696 Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013;2:e25595. [PMID: 24319634 DOI: 10.4161/onci.25595] [Cited by in Crossref: 71] [Cited by in F6Publishing: 80] [Article Influence: 7.1] [Reference Citation Analysis]
697 Galon J, Angell H, Bedognetti D, Marincola F. The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity 2013;39:11-26. [DOI: 10.1016/j.immuni.2013.07.008] [Cited by in Crossref: 567] [Cited by in F6Publishing: 600] [Article Influence: 56.7] [Reference Citation Analysis]
698 Loeffler JS, Durante M. Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol 2013;10:411-24. [PMID: 23689752 DOI: 10.1038/nrclinonc.2013.79] [Cited by in Crossref: 291] [Cited by in F6Publishing: 303] [Article Influence: 29.1] [Reference Citation Analysis]
699 Smilowitz HM, Sasso D, Lee EW, Goh G, Micca PL, Dilmanian FA. Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy. Cancer Immunol Immunother 2013;62:1187-97. [PMID: 23615842 DOI: 10.1007/s00262-013-1423-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
700 Taunk NK, Rimner A, Culligan M, Friedberg JS, Brahmer J, Chaft J. Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2017;6:178-85. [PMID: 28529900 DOI: 10.21037/tlcr.2017.03.05] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
701 Jabbour SK, Berman AT, Simone CB 2nd. Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2017;6:113-8. [PMID: 28529894 DOI: 10.21037/tlcr.2017.04.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]